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8Introduction
The prevalence of diabetes shows great vari-
ations in different populations. An epidemic of
non-insulin-dependent diabetes mellitus (type 2
diabetes) is occurring across the world, particu-
larly affecting developing countries and migrants
to westernised societies. The number of persons
with type 2 diabetes is expected to rise to more
than 200 million world-wide in the next 10 years
(WHO Study Group 1994).
Diabetes has traditionally been divided into
insulin-dependent (type 1) and non-insulin-de-
pendent (type 2) diabetes. Our knowledge about
the causes of diabetes, especially the role of
autoimmunity and genetics, has increased sig-
nificantly since the classification of diabetes in
1985 (WHO 1985). It has also become evident
that the old classification is too simple and that
diabetes is a much more heterogeneous disorder
than thought thus far. Therefore a WHO consul-
tation group proposed a new classification of dia-
betes in 1998 (Alberti and Zimmet 1998) and
introduced some new subgroups. About 10 % of
persons with adult onset diabetes have a slowly
progressing form of type 1 diabetes, also called
LADA (latent autoimmmune diabetes in adults)
(Tuomi et al.1993). Specific genetic defects as
different forms of MODY (maturity-onset dia-
betes in the young) and diabetes associated with
mutations in mitochondrial DNA may account
for about 5 % of all cases of diabetes (Hattersley
1998). A majority of patients with type 2 diabe-
tes has features of the metabolic syndrome, which
increases the risk of cardiovascular disease and
premature death (Reaven 1988). There is also
support for an interaction between type 1 and
type 2 diabetes with impact on the phenotype of
diabetes (Dahlqvist et al. 1989, Li et al. 1998).
Since the introduction of insulin in the 1920s,
which made survival possible for patients with
insulin-dependent diabetes, the long-term com-
plications of diabetes, i.e. retinopathy, nephropa-
thy, neuropathy and cardiovascular disease, have
become the major health problem for the patients
with type 1 diabetes. In patients with type 2 dia-
betes cardiovascular complications are common
and determine prognosis. In the industrialised
world diabetes is nowadays the most common
cause of severely impaired vision in people be-
low 65 years of age (Trautner et al. 1997) and
the most important cause of renal failure (Markell
et al.1992; Finnish Registry for Kidney Disease
1998). Diabetic neuropathy and the diabetic foot
are examples of diabetes-related problems with
great impact on health care costs and are often
associated with great disability and suffering for
the patient (Apelqvist et al. 1994).
Most studies on diabetic complications have
assumed that adult-onset diabetes is a more or
less homogeneous disease. We know now that
this is not the case. The question thus arises
whether it is possible to identify specific risk fac-
tors in subgroups of diabetes, which in addition
to hyperglycaemia increase the risk for chronic
diabetic complications and are some diabetic sub-
groups protected from the expected long-term
complications? This study was initiated to an-
swer these questions and to clinically character-
ise diabetic subgroups.
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1. Subclassification of diabetes
1.1. Towards a classification of diabe-
tes
Diabetes mellitus has been known for over
2000 years. Already from the earliest descrip-
tions, it was evident that diabetes was not a sin-
gle disorder. Indian descriptions from about 600
BC distinguish two forms of diabetes; one af-
fecting older, fatter people and the other affect-
ing thin people, who did not survive long. How-
ever, most descriptions in the ancient literature
relate to what is now recognised as insulin-de-
pendent diabetes (MacFarlane et al. 1997).
The successful use of insulin in rescuing
young patients supported the view that older pa-
tients could develop diabetes, but did not require
insulin for survival. In 1936, Himsworth pro-
posed that there are at least two distinct clinical
types of diabetes: an insulin-sensitive and an in-
sulin-insensitive type (Himsworth 1936). This
observation was confirmed after the development
of a bioassay for insulin in blood (Bornstein et
al. 1951). Thereafter diabetes was generally clas-
sified as “juvenile-onset”, insulin-dependent or
Table 1: Aetiological classification of diabetes (WHO 1998)  
 
  Classification 
I.  Type I (Beta cell destruction, usually leading to absolute 
insulin deficiency) 
 
A. Autoimmune 
1. Slowly progressive (LADA) 
2. Rapidly progressive 
 
B. Idiopathic 
II.  Type II (May range from predominantly insulin resistance 
with relative insulin deficiency to a predominantly secretory 
defect with or without insulin resistance) 
III.  Other specific types  
 
A. Genetic defects of the beta cell function 
(MODY, mitochondrial DNA) 
 
B. Genetic defects in insulin action 
(type A insulin resistance etc)  
 
C. Diseases of the exocrine pancreas 
(pancreatitis, hemocromatosis etc.) 
 
D. Endocrinopathies 
(Cushings syndrome, acromegaly etc) 
 
E. Drug- or chemical induced 
 
F. Infections 
 
G. Uncommon forms of immune -mediated diabetes 
(antibodies to insulin , anti-insulin receptor antibodies etc) 
 
H. Other genetic syndromes sometimes associated with diabetes  
IV.  Gestational hyperglycemia 
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“maturity-onset”, non-insulin-dependent diabe-
tes.
The US National Diabetes Data Group
(NDDG) presented a working classification in
1979 in which insulin-dependent (IDDM) dia-
betes was separated from obese and non-obese
forms of non-insulin-dependent (NIDDM) dia-
betes. Different forms of secondary diabetes
mellitus, impaired glucose tolerance (IGT) and
gestational diabetes (GDM) were also defined
(National Diabetes Data Group 1979). The
NDDG classification has been revised by WHO
in 1980 (WHO 1980) and 1985 (WHO 1985).
1.2. The new classification of diabetes
(WHO 1998)
Our knowledge about the causes of diabetes,
especially regarding the role of autoimmunity and
genetics in the pathogenesis of diabetes, has in-
creased markedly since 1985 (WHO 1985). It
became evident that the old classification is too
simple and that diabetes is a much more hetero-
geneous disorder than thought thus far (Beck-
Nielsen et al.1994; Zimmet 1995). In 1998 a
WHO consultation group (Alberti et al.1998)
proposed a new classification of diabetes (Table
1). In addition to the etiological classification,
the proposal introduces three clinical stages: non-
insulin requiring, insulin requiring for control
and insulin requiring for survival.
1.3. Autoimmunity in diabetes - Type
1 diabetes and LADA
The demonstration of insulitis; i.e.
lymphocythic infiltration of the islets of Langer-
hans in pancreata from recent juvenile-onset dia-
betic patients indicated that autoimmunity is in-
volved in the pathogenesis of this type of diabe-
tes (Gepts 1965). The subsequent detection of
antibodies directed against islet cells, islet cell
antibodies (ICA), suggested an immune reaction
directed towards the islet cells themselves
(Bottazzo et al. 1974). Later on antibodies to
other structures of the islets have been detected;
islet cell surface antibodies (ICSA) (Lernmark
et al. 1978), insulin autoantibodies (IAA) (Palmer
et al. 1983) and antibodies against glutamic acid
decarboxylase (GADA) (Baekkeskov et  al.
1987). ICA and GADA are markers of
autoimmune β-cell destruction and detected in
the majority of type 1 diabetic patients at the onset
of the disease (Groop et al. 1986; Landin-Olsson
et al. 1992; Tuomi et al. 1993).
A subgroup of patients with adult-onset dia-
betes has ICA and more often GADA. Several
studies have shown that positivity for ICA or
GADA is associated with relative insulin defi-
ciency (Irwine et al. 1977; Groop et al. 1986;
Groop et al. 1988; Landin-Olsson et al. 1990;
Tuomi et al. 1993; Zimmet et al. 1994). Within
10 years 50 % of newly diagnosed GADA-posi-
tive patients developed relative insulin deficiency,
defined as glucagon-stimulated C-peptide con-
centration <0.7 nmol/l, compared to 3 % of
GADA-negative patients (Niskanen et al. 1995).
Therefore, a proportion of adults who present
with type 2 diabetes seems to have a slowly pro-
gressing autoimmune type of diabetes also called
LADA (latent autoimmune diabetes in adults).
Epidemiological data demonstrate that
LADA accounts for about 10% of all cases with
diabetes thereby making it almost as common as
rapidly progressing type 1 diabetes (Turner et
al. 1997; Tuomi et al. 1999). The clinical char-
acteristics of patients with slowly progressing
type 1 diabetes (LADA) are seen in Table 2.
Table 2: Clinical features of slowly progressing  
autoimmune type 1      diabetes (LADA).  
 
Age at onset usually > 35 years 
Clinical presentation as non-obese type 2 diabetes 
Initial control with diet or oral agents 
Progressive deterioration of insulin secretion  
Positive markers of autoimmunity to the beta-cell 
 
Subclassification of diabetes
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1.4. Type 2 diabetes and the meta-
bolic syndrome
Type 2 diabetes is the most common form of
diabetes and also responsible for the explosive
increase in diabetes prevalence in many parts of
the world (King et al. 1993). The prevalence of
type 2 diabetes shows great variations in differ-
ent populations. In a Finnish study from the
Botnia region 85% of the diabetic patients were
diagnosed with type 2 diabetes, with a prevalence
of diabetes in subjects over 30 years of 3.9%
(Eriksson et al. 1992). In some ethnic groups such
as Pima Indians and Nauruans the prevalence of
diabetes in the adult population is much higher,
about 50 % (King et al. 1993).
Type 2 diabetes is a heterogeneous disease
where both impaired β-cell function and insulin
resistance contribute to the manifestation of the
disease (Beck-Nielsen et al. 1994). Epidemiologi-
cal studies provide evidence that the development
of type 2 diabetes is influenced both by adverse
environmental (lifestyle) factors and genetic sus-
ceptibility. Familial clustering of insulin resist-
ance and insulin deficiency suggests that these
defects are most likely genetically determined
(Groop et al. 1996a, Vauhkonen et al. 1998).
A majority of patients with type 2 diabetes
have features of the so-called metabolic syn-
drome, which has also been called “Syndrome
X”, the insulin resistance syndrome and the
deadly quartet (Reaven 1988; DeFronzo et al.
1991; Kaplan 1989). “Syndrome X” was re-in-
troduced in 1988 by Gerald Reaven, who sug-
gested that insulin resistance and compensatory
hyperinsulinaemia underlie the clustering of car-
diovascular risk factors like glucose intolerance,
hypertension and dyslipidaemia (Reaven 1988).
The syndrome is, however, much older, already
in 1923 Kylin described the clustering of hyper-
tension, hyperglycaemia and gout (Kylin 1923).
Several other components have subsequently been
associated with the syndrome, including obesity
Subclassification of diabetes
Table 3: The definition of the metabolic syndrome (WHO 1998) 
  Definition of the components 
A. In subjects with diabetes or 
IFG/IGT at least 2 of the 
following components: 
 
 1. Obesity high BMI (≥30 kg/m2) and/or high 
WHR (>0.9 in males; >0.85 in 
females) 
 2. Hypertension antihypertensive treatment and/or 
elevated blood pressure (>160 
mmHg systolic or > 90 mmHg 
diastolic) 
 3. Dyslipidemia high triglycerides (≥1.7 mmol/l)  
and/or low HDL cholesterol (<0.9 
mmol/l in males; <1.0 mmol/l in 
females) 
 4. Microalbuminuria AER ≥20 µg/min. 
B. In subjects with NGT also a 
criteria of insulin resistance 
glucose uptake below lowest 
quartile for background population 
under investigation 
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and especially abdominal obesity (Björntorp
1994), microalbuminuria (Groop et al. 1993;
Mykkänen et al. 1998), abnormalities in fibri-
nolysis and coagulation (Yudkin 1999) and
hyperuricemia (Modan et al. 1987; Vuorinen-
Markkola et al. 1992). The name insulin resist-
ance syndrome has been widely used and refers
to insulin resistance as a common denominator
of the syndrome (Modan et al. 1985; DeFronzo
et al. 1991; Haffner et al. 1992).
The prevalence of the metabolic syndrome has
varied markedly between different studies, most
likely because of the lack of accepted criteria for
the definition of the syndrome (Bonora et al.
1998; Rantala et al. 1999).  In 1998 WHO pro-
posed a unifying definition for the syndrome and
chose to call it the metabolic syndrome, rather
than the insulin resistance syndrome (Alberti et
al.1998). The reason was mainly that it was not
considered established that insulin resistance is
the cause of all the components of the syndrome.
The WHO proposal for definition of the meta-
bolic syndrome is shown in Table 3.
1.5. Maturity-onset diabetes of the
young
A mild form of diabetes in young people was
reported already in the pre-insulin era (Joslin
1916; Graham 1921). After the introduction of
sulfonylureas in the 1950s it was observed that
tolbutamide could improve or normalize glucose
tolerance in some young non-obese patients with
mild diabetes (Fajans et al. 1962; Fajans 1973).
In 1974, Tattersall reported an atypical form of
early-onset diabetes inherited in an autosomal
dominant pattern in three families (Tattersall
1974). The patients did not develop ketoacido-
sis, and diabetic complications were absent or
mild despite of a long duration of diabetes. The
patients were considered to belong to a subgroup
of diabetes called maturity-onset diabetes of the
young (MODY) (Tattersall et al. 1975). A diag-
nosis of MODY was considered if diabetes had
been diagnosed before the age of 25 (also in 1-2
members of the family), fasting hyperglycaemia
had been normalised without insulin treatment
over 2 years and the patients had a strong family
Subclassification of diabetes
Table 4: Comparison of the most common subtypes of MODY. 
 
 MODY1 MODY2 MODY3 
Chromosomal location 20q 7p 12q 
Gene HNF4-α glucokinase HNF1-α 
Proportion of MODY* ~ 10 % ~ 15 % ~ 60 % 
Onset of hypergycemia adolescence, 
early 
childhood 
early 
childhood 
adolescence 
early 
childhood 
Severity of diabetes progressive, 
may be severe 
mild, 
minor 
deterioration 
progressive, 
may be severe 
Pathophysiology beta-cell 
dysfunction 
beta-cell 
dysfunction, 
impaired 
glucose-
sensing 
beta-cell 
dysfunction 
Microvascular 
complications 
frequent rare frequent 
Modified from Hattersley AT: Diabet. Med. 15:15 -24,1998; * data from Scandinavia (Lehto et al. 1999) 
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history of diabetes (often in 3 generations).
In 1991, Bell et al. demonstrated linkage to
the long arm of chromosome 20 (MODY1) in a
large MODY-family, the so-called RW family
from Ann Arbor (Bell et al. 1991). It was later
on shown that this linkage was due to mutations
in a liver-specific transcription factor gene, the
hepatocyte nuclear factor (HNF-4α) (Yamagata
et al. 1996b). Soon after the demonstration of
linkage to chromosome 20, a positive linkage to
the short arm of chromosome 7 (MODY2) was
reported in some families with early-onset dia-
betes (Froguel et al. 1992). This region harbours
the glucokinase gene, and mutations in this gene
are responsible for MODY2 (Vionnet et al. 1992).
In 1995, Vaxillaire et al. performed a genome
wide scan in 12 MODY families that were not
linked to chromosome 20 or 7. In several of these
families linkage to the long arm of chromosome
12 (MODY3) could be observed (Vaxillaire et
al. 1995). Mutations in another transcription fac-
tor gene, HNF-1α, are the cause of MODY3
(Yamagata et al.1996a). Mutations in the gene
for insulin promoter factor 1 (IPF1), located to
chromosome 13 explain MODY4 (Stoffers et al.
1997a). Interestingly, pancreatic agenesis has
been reported in a homozygous IPF1 mutation
carrier (Stoffers et al. 1997b). Finally, mutations
in the HNF-1β gene (heterodimer with HNF-1α)
are considered responsible for MODY5
(Horikawa et al. 1997). Of note, this form of
MODY is also associated with severe cystic kid-
ney disease or urogenital abnormalities (Iwasaki
et al. 1998). Obviously, there are MODY genes
not yet detected, as there are MODY families
without linkage to any of the known MODY
genes (Hattersley 1998; Lehto M et al 1999b).
The exact prevalence of MODY remains un-
known, but MODY is thought to account for less
than 5 % of diabetes (Velho et al. 1998). In Scan-
dinavia MODY3 seems to be the most common
form of MODY (Lehto M et al. 1999b). Patients
with MODY1 and MODY3 diabetes are usually
diagnosed in adoloscence or early adulthood.
They are characterised by a defect in insulin se-
cretion, and many patients are treated with insu-
lin (Lehto M et al. 1997; Hattersley 1998; Velho
et al.1998). Gestational diabetes seems to be com-
mon in MODY3 families (Lehto et al. 1997).
Most patients with MODY2 are diagnosed with
mild fasting hyperglycaemia in childhood or early
adulthood and can often be managed by diet only
(Velho et al. 1997). The hyperglycaemia in
MODY2 patients is thought to reflect a defect in
glucokinase-mediated sensing of glucose in the
pancreatic β-cell (Byrne et al. 1994). Features of
the metabolic syndrome are not characteristic for
patients with MODY (Velho and Froguel 1998).
Interestingly, triglyceride concentrations were
surprisingly low in a Swedish MODY1 family
(Lehto M et al. 1999a). A comparison of the most
common MODY subtypes can be seen in the
Table 4.
 Mitochondial DNA mutations: Human cells
contain hundreds to thousands of mitochondria,
each containing its own DNA as a small double-
stranded molecule. As the tail of the sperm, which
contains the paternal mitochondia, is left out-
side the oocyte during fertilisation, the human
mitochondrial DNA is exclusively transmitted
from the mother. The mitochondrial DNA is
highly vulnerable to mutations. More than 100
mutations are known and are associated with
various clinical syndromes, including maternally
inherited diabetes and deafness (MIDD)
(Reardon et al. 1992; Van den Ouweland et
al.1992).
2. Chronic diabetic complica-
tions
2.1. Pathogenesis of complications
The natural history of both type 1 and type 2
diabetes is darkened by the appearance of chronic
complications. These include such diabetes-spe-
cific complications as retinopathy, nephropathy
and neuropathy. These have been named micro-
vascular complications, even though the cause
of neuropathy seems to be more complex than
strictly a disorder of small blood vessels.
Macrovascular complications are not specific to
diabetes, but the atherosclerotic process seems
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to be more pronounced in diabetic patients
(Stamler et al. 1993; Koivisto et al. 1996).
Hyperglycaemia, the common feature of all
types of diabetes, appears to cause tissue dam-
age by both acute reversible changes in cellular
metabolism and cumulative, irreversible changes
in macromolecules. The possible biochemical
mechanisms include activation of the polyol path-
way, activation of protein kinase C (PKC), for-
mation of glycation endproducts and increased
oxygen stress (Giardino et al.1997).
The polyol pathway: Through the polyol
pathway, glucose is converted to sorbitol by al-
dose reductase, which is the rate-limiting enzyme
(Greene et al. 1987). Aldose reductase is found
in the nervous system, retina, glomerulus and
the blood vessels, i.e. in tissues, which do not
require insulin for glucose uptake. Sorbitols and
other polyols accumulate intracellularily, lead-
ing to osmotic damage and swelling. Aldose re-
ductase inhibitors have improved neuropathy to
some extent in diabetic patients, including im-
provement in nerve fiber density and nerve con-
duction velocity (Greene et al. 1999).  On the
other hand, no convincing results have been seen
regarding nephropathy (Passariello et al. 1993;
Rangathan et al. 1993) or retinopathy (Sorbinil
Retinopathy Trial Reasearch Group 1990).
Protein kinase C (PKC): Hyperglycaemia in-
duces synthesis of diacylglycerol, which can ac-
tivate PKC (Lee at al. 1989). An activation of
PKC has been implicated in many processes rel-
evant to diabetic complications, including regu-
lation of vascular permeability and flow, in-
creased production of cytokines and increased
synthesis of basement membranes (Giardino et
al. 1997).
Advanced glycation endproducts (AGE):
Hyperglycaemia leads to the formation of
glycation products through a non-enzymatic
process in which glucose is attached to amino
groups of proteins. The early glycation products
can by rearrangement form more stable products.
Those formed on collagen, DNA and other long-
lived macromolecules slowly undergo further
chemical rearrangements to form AGEs
(Brownlee et al. 1984). The formation of AGEs
can contribute to tissue damage in several ways,
including release of growth factors, stimulation
of synthesis of extracellular matrix and cellular
hypertrophy and hyperplasia. In animals with
experimental diabetes administration of
aminoguanidine, an inhibitor of AGE formation,
prevents development of retinopathy (Brownlee
1992) and the expected rise in albuminuria
(Edelstein et al. 1992) and shows improvement
Chronic diabetic complications
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. A model for pathogenesis of microvascular diabetic complications. 
Repeated changes 
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in nerve condition velocity (Yagihashi et al.
1992). Yet we have no results from clinical tri-
als.
Increased oxidative stress: Hyperglycaemia
also leads to increased oxidative stress leading
to peroxidation of lipid membranes, proteins and
DNA (Van Dam et al. 1995).
Genetic susceptibility
Despite the important impact of hyperglycae-
mia on diabetic complications, other factors un-
doubtedly contribute. There are patients with
longstanding hyperglycaemia without complica-
tions and patients with short duration of disease
who seem to be very prone to complications.
Genetic factors have been suspected as one ex-
planation for the differences in susceptibility to
complications.  Diabetic nephropathy has been
found to aggregate in families (Borch-Johnsen
et al. 1992, Fioretto et al. 1999). Ethnic differ-
ences seem to exist in the occurrence of diabetic
nephropathy (Nelson et al. 1988; Ballard et al.
1988; Kunzelman et al. 1989; Humphrey et
al.1989) and retinopathy (Haffner et al. 1988;
Nelson et al. 1989). The finding of elevated urine
albumin excretion rate (AER) in non-diabetic
relatives of type 2 diabetic patients also suggests
an important role of hereditary factors for the
development of albuminuria (Forsblom et al.
1999). In addition to hyperglycaemia and genetic
susceptibility, many other factors have been as-
sociated with the evolution of diabetic complica-
tions. These risk factors will be evaluated in the
sections for the different complications. A hypo-
thetical model for the development of chronic
microvascular diabetic complications is depicted
in Figure 1.
2.2. Retinopathy
Diabetes results in characteristic lesions in
the retinal blood vessels. This can result in for-
mation of microaneurysms, haemorrhages and
increased leakage, causing retinal edema and li-
pid exudates. These changes are defined as back-
ground retinopathy (NPDR). They do not
threaten visual acuity unless they are located in
the macular region, where they can cause macu-
lar edema. Capillary closure can lead to areas of
impaired perfusion and ischaemia, which can
result in retinal infarcts and formation of new
vessels, defined as proliferative retinopathy
(PDR)(Fig.2). New vessels can cause intraocular
bleeding and impair vision. The formation of fi-
brous tissue may eventually cause retinal detach-
ment and severe visual impairment (Forrester et
al. 1997).
Epidemiology
Population-based studies of patients with dia-
betes show great variation in the reported preva-
lence of retinopathy. Differences in age at diag-
nosis, duration of diabetes, treatment and gly-
caemic control could all influence the prevalence
(Klein et al. 1984a, Agardh et al. 1989;
Henricsson et al. 1996). The method used to de-
tect retinopathy seems to be crucial. Photogra-
phy has been demonstrated to be superior to
ophthalmoscopy for detection of early diabetic
changes (Moss et al. 1985; Kinyoun et al. 1992).
Valuable information has been obtained from
prospective follow-up studies with standardised
grading of retinal photographs. The Wisconsin
Epidemiological Study of Diabetic Retinopathy
(WESDR) (Klein et al. 1984a; Klein et al. 1984b)
followed both younger-onset  (diagnosed before
30 years of age, n=996) and older-onset diabetic
patients (diagnosed after 30 years of age) with
(n=673) or without (n=692) insulin treatment.
In the younger-onset group there was almost no
retinopathy during the first 5 years of disease,
but thereafter the rise was rapid and by 15 years
more than 90 % of the patients had some degree
of retinopathy. In contrast, over 20% of the older-
onset patients had some signs of retinopathy dur-
ing the first 5 years and after a long duration
still 20 % of the patients did not have signs of
retinopathy. The prevalence of PDR rose to about
50% in the younger-onset patients and to about
10-30 % in the older-onset patients after 25 years
of diabetes. In the insulin-treated older-onset
patients those treated with insulin had higher
prevalence of retinopathy than the non-insulin
treated.  In a cross-sectional study from Sweden,
using the same classification of retinopathy, the
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prevalence of retinopathy in younger-onset pa-
tients was 64%, and in the older-onset patients
57% in insulin-treated and 26% in non-insulin
treated patients, respectively (Henricsson et al.
1996). In the United Kingdom Prospective Dia-
betes Study (UKPDS) diabetic retinopathy was
detected in about one third of newly diagnosed
type 2 diabetic patients (Kohner et al. 1998).
The prevalence of retinopathy varies among
different racial or ethnic groups. The Pima Indi-
ans in Arizona and Mexican Americans in San
Antonio, Texas, with type 2 diabetes have a sig-
nificantly higher prevalence of retinopathy than
non-Hispanic white patients from the WESDR
population (Haffner et al. 1988; Nelson et al.
1989).
There are limited data on retinopathy in dia-
betic subgroups, i.e. patients with MODY or
LADA. In a study of 24 patients with MODY3
diabetes proliferative retinopathy based on
ophthalmoscopy was seen in 5 patients (21%)
(Velho et al. 1996). In patients with MODY1
diabetes retinopathy is frequently described
(Hattersley 1998, Iwasaki et al. 1998) whereas
in MODY2 retinopathy seems to be rare (Page
et al. 1995; Velho et al. 1996; Velho et al. 1997).
Risk factors for diabetic retinopathy
Hyperglycaemia: A relationship between hy-
perglycaemia and a higher prevalence and inci-
dence and progression of retinopathy has been
seen in both type 1 and type 2 diabetes (Pirart
1978; Klein et al. 1984a; Agardh et al. 1994;
Henricsson et al. 1996; Stratton et al. 2001). The
Diabetes Control and Complications Trial
(DCCT 1995a) reported a reduction in the de-
velopment of retinopathy by 76 %, and in pro-
gression to severe non-proliferative or prolifera-
tive retinopathy by 47 % in patients intensively
treated compared to conventionally treated pa-
tients during a follow-up of 6.5 years. In the
Stockholm Study the need for photocoagulation
was reduced in intensively treated compared to
conventionally treated patients (Reichard et al.
1993). In the Kumamoto Study intensive insulin
treatment of type 2 diabetic patients was associ-
ated with less worsening of retinopathy compared
to the group with conventional insulin treatment
(Shichiri et al. 2000). Although improvement in
glycaemic control retards the development and
progression of retinopathy, there have been re-
Chronic diabetic complications
 
 
 
 
 
 
 
 
 
 
 
 
 
  
   
 
      
      
      
       
 
 
 
 
Figure 2. Role of hyperglycaemia and hypertension in the evolution of diabetic retinopathy. Modified from E. 
Kohner 1993. 
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ports on worsening of retinopathy after rapidly
improved glycaemic control both in type 1 and
type 2 diabetes (Lauritzen et al. 1983; DCCT
1998; Henricsson et al. 1999). The greatest risk
of progression was related to the magnitude of
the lowering of HbA1c (Henricsson et al 1999).
The mechanisms by which the rapid improve-
ment in glycaemia can impair retinopathy is not
entirely clear but it has been suggested to involve
altered rheological conditions (Grunwald et al.
1995).
Duration of diabetes: The association be-
tween duration of diabetes and retinopathy has
been seen in many studies especially in type 1
diabetes (Pirart 1978; Klein et al. 1984a). In type
2 diabetes retinopathy is seen in many patients
already at diagnosis (Kohner et al. 1998). This
probably reflects the difficulties in determining
the exact duration of diabetes.
Hypertension: A relationship between el-
evated blood pressure and retinopathy has also
been seen in several studies both in type 1 (Klein
et al. 1984a; Agardh et al. 1994) and type 2 dia-
betic patients (Klein et al. 1984b; Teuscher et al.
1988; Hamman et al. 1989). In a cohort study, a
10 mmHg increase in systolic blood pressure was
significantly associated with increased incidence
of retinopathy in subjects with younger-onset
diabetes (age at diagnosis below 30 years), but
not in subjects with older-onset diabetes (Klein
et al. 1995a). In the UKPDS, tight blood pres-
sure control decreased significantly the progres-
sion of retinopathy (UKPDS 1998).
Both hypertension and hyperglycaemia in-
crease the retinal blood flow, which is involved
in the evolution of diabetic retinopathy (Fig. 2).
In contrast, conditions that reduce retinal blood
flow seem to protect from advanced retinopathy;
these include moderate carotid stenosis and raised
intraocular pressure (Parving 1983; Grunwald
et al. 1990).
Nephropathy: There is a relationship be-
tween the development of nephropathy and retin-
opathy. When overt diabetic nephropathy is
present, almost all patients already have a con-
comitant proliferative retinopathy (Krolewski et
al. 1986). However, about 30 % of patients with
proliferative retinopathy do not show signs of ne-
phropathy (Agardh et al. 1987; Kostraba et al.
1991), indicating that the development of these
two complications may follow different time
courses or that partly different mechanisms may
be involved (Mosier et al. 1997).
Smoking: The effect of smoking on the risk
of retinopathy is controversial. Only a few stud-
ies have found a harmful effect (Sjølie 1985;
Chaturvedi et al. 1995). In contrast, in the cross-
sectional and the prospective Wisconsin study no
association between smoking and retinopathy was
seen (Moss et al. 1996).
Other factors: An association between retin-
opathy and some other factors such as pregnancy
(Klein et al. 1990; Lövestam-Adrian et al. 1997)
and age at diagnosis (Krolewski et al. 1986;
Agardh et al. 1989; Kostraba et al. 1989) has
been suggested, but results from studies are con-
flicting. Studies regarding the impact of lipids
and lipoproteins on retinopathy have been incon-
sistent (Klein et al. 1997).
2.3. Nephropathy
The hallmark of renal damage in diabetes is
increased excretion of proteins, mainly albumin,
in the urine. The natural history of diabetic ne-
phropathy has been viewed as a descending path
from normoalbuminuria to microalbuminuria and
overt proteinuria and eventually to end-stage re-
nal disease (ESRD) (Fig. 3). In 1986 a consen-
sus was reached about the term microalbumiuria,
which was defined as urine AER 20-200 µg/min
in a timed overnight or 30-300mg/24h in a 24-h
urine collection (Mogensen et al.1986). Urine
AER exceeding these values is called
macroalbuminuria and considered a sign of mani-
fest diabetic nephropathy.
Epidemiology
Approxmately 35-45% of patients with type
1 diabetes will develop diabetic nephropathy
during a follow-up of about 40 years of diabetes
(Andersen et al. 1983; Krolewski et al. 1985).
The incidence of diabetic nephropathy increases
rapidly after duration of 10 years and begins to
decrease after about 20 years of diabetes
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(Andersen et al. 1983). The prevalence of
microalbuminuria rises from below 10% during
the first years of diabetes to about 50% of pa-
tients after duration of 20 years. The prevalence
of ESRD starts to rise after duration of 15 years,
reaching a peak of about 20 % after duration of
35 years (Krolewski et al. 1985). Compared to
type 1 diabetic patients, in whom
microalbuminuria is rare during the first years,
microalbuminuria is a common feature in type 2
diabetic patients already at the diagnosis of dia-
betes. In Caucasian newly diagnosed type 2 dia-
betic patients, the prevalence of
microalbuminuria is about 20-30% (Uusitupa et
al. 1987; UKPDS 1993). The high prevalence of
microalbuminuria in type 2 diabetes may be due
to difficulties in defining the exact duration in
type 2 diabetes, the high prevalence of non-dia-
betic renal disease (Parving et al. 1992) and the
presence of the metabolic syndrome, in which
microalbuminuria has been related to more gen-
eralised vascular damage (Nannipieri et al. 1997).
There are few studies on the presence of dia-
betic nephropathy in patients with MODY,
LADA or other diabetic subgroups. In a study of
26 patients with MODY3 diabetes 5 patients
(19%) had dipstick positive proteinuria (lower
limit of detection 2.5-3.0 mg/dl) (Velho et
al.1996). In patients with MODY2 diabetes ne-
phropathy has been virtually non-existing (Page
et al. 1995; Velho et al. 1996; Velho et al. 1997).
Type 2 diabetic patients with ICA (LADA)
showed a significantly lower prevalence of albu-
minuria (micro- or macroalbuminuria) and lower
AER compared to type 2 diabetic patients with-
out ICA 5 years after the diagnosis of diabetes
(Gottsäter et al. 1996).
Risk factors
Hyperglycaemia: Poor glycaemic control has
been associated with the development of
microalbuminuria both in type 1
(Microalbuminuria Collaborative Study Group
1993; Mathiesen et al. 1995; Agardh et al. 1997)
and in type 2 diabetic patients (Niskanen et al.
1996; Gall et al. 1997; Forsblom et al. 1998a).
In the DCCT study intensive therapy reduced the
occurrence of microalbuminuria by 39% and that
of albuminuria by 54% (Diabetes Control and
Complication Trial 1993). In Type 2 diabetic
patients intensified therapy has been associated
with a reduction in the progression of
microalbuminuria (Ohkubo et al. 1995).
Duration of diabetes: The duration of dia-
betes has been associated with the development
of nephropathy in both type 1 (Andersen et al.
1983) and type 2 (Ballard et al. 1988) diabetic
patients. Progression from microalbuminuria to
overt nephropathy has also been reported to oc-
cur in a majority of type 1 diabetic patients in
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The progression of albumin excretion (AER), risk factors and prognosis. 
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follow-up studies (Parving et al. 1982; Mogensen
et al. 1984). However, all patients with
microalbuminuria and long duration of diabetes
do not progress. Signs and symptoms of insulin
resistance seem to be more common in patients
who progress to nephropathy (Forsblom et al.
1992).
Genetic factors: The prevalence of neph-
ropathy in type 2 diabetes seems to be influenced
by ethnic factors; in Pima Indians the cumula-
tive incidence of diabetic nephropathy and ESRD
after 20 years duration was 50 and 15%, respec-
tively, compared to about 25 and 6 %, respec-
tively, in Caucasians  (Nelson et al. 1988; Ballard
et al. 1988; Kunzelman et al. 1989; Humphrey
et al. 1989). Familial aggregation of nephropa-
thy has been demonstrated in both type 1
(Seaquist et al 1989; Borch-Johnsen et al. 1992,
Fagerudd et al. 1998) and type 2 diabetes (Pettitt
et al 1990; Faronato et al 1997).
Hypertension: The importance of hyperten-
sion in the development of nephropathy is diffi-
cult to assess, as elevation of blood pressure gen-
erally follows the development of nephropathy
in type 1 diabetic patients (Poulsen et al. 1994).
In type 2 diabetic patients microalbuminuria and
hypertension often coincide as components of the
metabolic syndrome (Groop et al. 1993; Alberti
et al. 1998).
Gender: Male sex has been associated with
an increased risk of diabetic nephropathy in both
type 1 (Jacobsen et al. 1999) and type 2 (Gall et
al. 1997; Forsblom et al. 1998a) diabetic patients.
Smoking: Smoking seems to increase the risk
of nephropathy in type 1 diabetes (Chase et al.
1991; Microalbuminuria Collaborative Study
Group 1993). In type 2 diabetic patients the re-
sults have been conflicting (Gall et al. 1997;
Forsblom et al. 1998a).
Dietary protein intake: Reduction of dietary
protein intake seems to have a beneficial effect
on the rate of loss of kidney function in diabetic
renal disease (Walker et al. 1989; Zeller et al.
1991; Pedrini et al. 1996).  The conducted stud-
ies have been small and further studies are needed
to define the role of protein restriction in dia-
betic nephropathy. The effect is thought to be
mediated by a reduction in glomerular
hyperfiltration.
Lipids and lipoproteins: In type 1 diabetic
patients multiple lipid abnormalities are seen in
patients with nephropathy, but little is known
about the role of lipid abnormalities in the de-
velopment of diabetic nephropathy (Groop et al.
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Table 5: Clinical classification of neuropathy. 
 
Classification  Symptoms Signs Prognosis 
1.Distal symmetrical asymptomatic, 
altered 
sensation, 
pain 
normal, 
sensory loss, 
muscle atrophy 
progressive, 
neuropathic 
ulcer, Charcot 
arthropathy 
2. Autonomic asymptomatic, 
gustatory 
sweating, 
hypotension, 
gastroparesis, 
diarrea, 
impotence etc 
abnormal 
autonomic 
functions 
progressive, 
disabling, 
increased 
mortality 
3.Mononeuropathies mucle 
weakness, 
pain 
femoral 
amyotrophy, 
ocular palsies, 
truncal 
radiculopathy 
slow recovery 
4.Acute painful  
distal 
pain, sensory 
loss, weight 
loss 
sensory loss slow recovery 
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1996b). In type 2 diabetic patients dyslipidaemia
often clusters with microalbuminuria as part of
the metabolic syndrome (Kuusisto et al. 1995).
2.4. Neuropathy
Diabetic neuropathy includes a spectrum of
clinical manifestations, which can vary from
asymptomatic findings to disabling disease
(Vinik et al. 2000). The clinical classification and
characteristics of diabetic neuropathy are shown
in Table 5. The most common form is distal, sym-
metric polyneuropathy. The complex nature of
neuropathy and the lack of a unifying definition
complicate the comparison of study results on
diabetic neuropathy. Although efforts have been
made to define diabetic neuropathy (Report and
recommendations of the San Antonio conference
on diabetic neuropathy 1988), the definitions
used in different studies show great variations.
Commonly used tests for the examination of dia-
betic neuropathy are shown in Table 6. As the
use of electrophysiological tests are difficult in a
clinical setting most studies have used a combi-
nation of a scored questionnaire, a standardised
clinical examination and some method of quan-
titative sensory testing. Some of these combina-
tions of tests have reached wider use, as the
Michigan Neuropathy Screening Instrument
(MNSI) and the Michigan Diabetic Neuropathy
Score (MDNS) (Feldman et al. 1994) and the
Neuropathy Disability Score (NDS) and Neuropa-
thy Symptom Score (NSS) used in the UK hos-
pital clinic study (Young et al. 1993). Monofila-
ment testing (cutaneous pressure perception) in
a standardised setting has also been widely used
in order to identify diabetic patients at high risk
for foot ulceration (Kumar et al. 1991; Pham et
al. 2000).
Epidemiology
 
In unselected populations the prevalence of
diabetic neuropathy ranges between 10 and 90
% depending upon definitions and the methods
used to detect neuropathy (Feldman et al.1994).
In a study by Pirart 8% of the patients had evi-
dence of neuropathy at diagnosis while the preva-
lence was 50 % after a follow-up of 25 years
(Pirart 1978). In studies where distal neuropa-
thy was defined as the presence of significant
symptoms and/or abnormalities in the physical
examination the prevalence has been 20-35%
both in type 1 and type 2 diabetic patients (Ziegler
et al. 1993; Young et al. 1993; Tesfaye et al. 1996;
Fedele et al. 1997). The prevalence of autonomic
neuropathy has also shown great variations prob-
ably depending on different methods used and
varying populations studied. In type 2 diabetic
patients Töyry et al. found parasympathetic neu-
ropathy in 5 % of patients at diagnosis and 65%
after a follow-up of 10 years (Töyry et al. 1996).
Although pathological testresults are seen in
many patients, symptomatic autonomic neuropa-
 
 
Table 6: Commonly used tests for diabetic neuropathy.  
Symptoms
 
history or scored questionnaire
 
  
Clinical examination
 
tendon reflexes, sensory testing for 
vibration, pain, temperature, light touch
 
  
Quantitive sensory testing
 
threshold for vibration, thermal sensation, 
light touch
 
  
Electrophysiologic tests
 
motor and sensory conduction, needle 
electromyography
 
 
 
Autonomic tests
 
cardiovascular, sudomotor, vasomotor tests 
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thy is relatively rare.
Neither have the studies on neuropathy taken
into account heterogeneity of diabetes. In the
French study of MODY3 patients only one out
of 27 patients showed clinical signs of periph-
eral neuropathy (Velho et al. 1996). In MODY2
neuropathy seems to be very rare (Page et al.
1995; Velho et al. 1996; Velho et al. 1997).
Antibodies to glutamic acid decarboxylase
(GADA) have been associated with presence of
peripheral neuropathy in type 1 diabetic patients
(Kaufman et al. 1992). This finding is interest-
ing, as immunological mechanisms have been
suggested to play a role in the pathogenesis of
neuropathy, and glutamic acid decarboxylase
(GAD) is widely distributed throughout the pe-
ripheral and autonomic nervous system. Further
studies have not confirmed an association be-
tween GADA and diabetic neuropathy (Zanone
et al. 1994, Roll et al. 1995).
Risk factors for neuropathy
Hyperglycaemia: Poor glycaemic control has
been associated with increased risk of neuropa-
thy in many studies of both type 1 (Tesfaye et al.
1996; Dyck et al.1999) and type 2 diabetes
(Partanen et al. 1995; Adler et al.1997). In the
DCCT study intensive therapy, with HbA1c about
7%, in type 1 diabetic patients reduced the ap-
pearance of neuropathy by 69 % (DCCT 1993).
In the Kumamoto study, comparing intensive and
conventional insulin therapy in type 2 diabetic
patients, the patients with intensive therapy
showed significant improvement in nerve con-
dition velocity and vibration threshold compared
to the conventional group (Shichiri et al. 2000).
A model for the pathogenesis of neuropathy and
the importance of hyperglycaemia is shown in
Figure 4.
Duration: The prevalence of neuropathy
seems to increase with longer duration of dis-
ease (Pirart 1978; Young et al. 1993; Partanen et
al.1995).
Age: Increased age of the patients has been
associated with neuropathy in some studies
(Ziegler et al. 1993; Adler et al.1997).
Smoking: Smoking is thought to have a toxic
effect on peripheral nerves. However, the results
regarding smoking as a risk factor for neuropa-
thy are conflicting both in type 1 and type 2 dia-
betic patients (Mitchell et al. 1990; Sands et al.
1997). In the large EURODIAB study cigarette
smoking was associated with neuropathy (Tesfaye
et al. 1996).
Height: In some studies increased height has
been associated with neuropathy (Tesfaye et al.
1996; Adler et al. 1997). Height has been inter-
preted as a marker of neuronal length and could
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Figure 4. A model for the pathogenesis of diabetic neuropathy. Modified from Sima et al. 
1999. NCV: nerve condition velocity.  
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imply an increased vulnerability for diabetic dam-
age to the nerve. Height is also associated with
greater pressure in lower extremities, which could
decrease capillary blood flow (Richardson 1988).
C-peptide: Both insulin and C-peptide seem
to have neuroprotective effects (Ido et al. 1997).
This theory is supported by the results from a
Finnish 10-year follow-up study, where the pa-
tients who developed neuropathy in addition to
poor metabolic control also had lower baseline
insulin values (Partanen et al. 1995).
2.5. Cardiovascular disease
The clinical manifestations of CVD include
coronary heart disease (CHD), cerebrovascular
disease and peripheral vascular disease
(PVD).The underlying disease mechanism is
accelerated atherothrombosis. The atherosclerotic
process starts from fatty streaks, consisting of
intimal deposits of lipids and macrophages with
lipid droplets (foam cells), gradually developing
into more advanced plaques. The process ends
up in a complicated atherosclerotic lesion, which
through a plaque rupture and thrombosis can
cause an acute myocardial infarction (Stary et
al. 1994; Stary et al. 1995).
Atherosclerotic lesions in diabetic patients are
histologically similar to those in non-diabetic
subjects, but appear to be more extensive and se-
vere than in non-diabetic subjects. This is illus-
trated by a Finnish 7-year follow-up study in
which patients with type 2 diabetes without prior
myocardial infarction had a risk of infarction
similar to that among non-diabetic men with a
previous infarction (Haffner et al. 1998).
The prevalence of CVD is highly dependent
upon which methods are used to detect the dis-
ease (Table 7). CHD, the most important mani-
festation of CVD, represents a wide spectrum
from angina pectoris, myocardial infarction and
sudden death to silent myocardial ischaemia
(Naka et al. 1992). Silent myocardial ischaemia
has a reported prevalence of 10-20 % in diabetic
populations  compared with 1-4 % in non-dia-
betic populations (Janand-Delenne et al. 1999).
The atherosclerotic process can be studied
non-invasively by the use of imaging techniques
such as measuring the intima-media thickness
by ultrasound (Wendelhag et al. 1991), and mag-
netic resonance imaging (Fayad et al. 2000).
Measurement of ankle-brachial index (ABI) has
also been used to detect asymptomatic athero-
sclerosis (Leng et al. 1996).
Epidemiology
Type 1 diabetes: The prevalence of CVD has
varied markedly depending on the criteria of
CVD, duration of diabetes and the impact of dia-
betic nephropathy. In the EURODIAB study the
overall prevalence of CVD in type 1 diabetic
patients was 10%, increasing with age and dura-
tion and with a sixfold variation between differ-
ent European centres (Koivisto et al. 1996). The
cumulative CHD mortality by age  55 years was
35 % in type 1 diabetic men and women com-
pared to 8 and 4 %, respectively,  in nondiabetic
men and women (Krolewski et al. 1987). Dia-
betic nephropathy markedly increases the risk of
CVD: in a follow-up study the risk ratio of CHD
death was 37 in patients with proteinuria com-
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Table 7: Methods to study prevalence of coronary heart disease, silent myocardial ischaemia 
and atherosclerosis.  
 
Clinical CHD Silent myocardial 
ischaemia 
Atherosclerosis 
medical history, 
typical symptoms, 
resting ECG, 
causes of death 
exercise ECG,  
thallium scintigraphy, 
continuos 24-h ECG 
monitoring (Holter), 
coronary angiography 
ankle-brachial index, 
intima-media thickness, 
magnetic resonance 
imaging 
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pared to 4.2 in patients without proteinuria
(Borch-Johnsen et al. 1987). Dyslipidaemia has
been suggested as a possible mechanism behind
the increased CVD risk in patients with neph-
ropathy. In connection with diabetic nephropa-
thy total and LDL cholesterol, triglycerides and
ApoB concentrations are increased while HDL
cholesterol is reduced (Groop et al. 1996b). In
patients without diabetic nephropathy poor meta-
bolic control predicted CHD events independ-
ently of other cardiovascular risk factors (Lehto
S et al. 1999).
Type 2 diabetes: In patients with type 2 dia-
betes the age-adjusted, cause-specific mortality
for CHD is two to four times higher than in non-
diabetic control groups (Kannel et al. 1979;
Stamler et al. 1993; Nathan et al. 1997). The
relative risk has been even greater for women in
many studies.  The risk for stroke and peripheral
vascular disease is also increased in diabetic pa-
tients (Kannel et al. 1979; Brand et al. 1989,
Siitonen et al. 1993). The prevalence of CVD is
also influenced by  the prevalence  of CVD in
the background population (WHO multinational
Study of Vascular Disease in Diabetics 1985;
Zimmet et al. 1997).
Again, few studies have considered hetero-
geneity of diabetes when studying the presence
of CVD. The prevalence of CHD in patients with
MODY diabetes has been difficult to assess as
the study populations have been small and the
patients have been  relatively young. Patients with
LADA have shown a more favourable cardio-
vascular risk profile compared to other type 2
diabetic patients (Gottsäter et al. 1996; Tuomi et
al. 1999).
Risk factors for cardiovascular disease in
type 2 diabetic patients
The classic risk factors: Data from popula-
tion studies indicate that the major cardiovascu-
lar risk factors in non-diabetic populations,
namely smoking, hypertension and
hypercholesterolemia, also operate in diabetic
subjects (Stamler et al. 1993). Genetic factors are
obviously also important as the prevalence is in-
fluenced by the background population (WHO
Multinational Study of Vascular Disease in
Diabetics 1985). In the MRFIT (Stamler et al.
1993) where 5000 diabetic and 350000 non-dia-
betic subjects were followed up for 12 years, the
cardiovascular death rate increased highly sig-
nificantly with the number of risk factors (systolic
blood pressure, smoking and total cholesterol)
in both diabetic and non-diabetic men. However,
the incidence of CVD death was increased 2-3
fold in the diabetic men for each combination of
risk factors (Fig. 5). The traditional risk factors
do not explain all the excess risk of CVD disease
in patients with diabetes. Therefore, also other
risk factors must be operative in diabetic patients.
Hyperglycaemia: Several prospective stud-
ies mainly in type 2 diabetic patients have shown
that glycaemic control influences the risk of CVD
(Klein 1995b; Wei et al. 1998; Laakso 1999). In
the UKPDS the most important risk factor for
CHD was high LDL cholesterol, followed by low
HDL cholesterol and hyperglycaemia (Turner et
al. 1998). In a Finnish prospective study, poor
glycaemic control in addition to hypertension and
dyslipidaemia predicted fatal and non-fatal stroke
(Lehto S et al. 1996). The results from prospec-
tive studies indicate that hyperglycaemia is re-
lated to macrovascular disease, but the risk of
macrovascular disease seems to be smaller than
the risk associated with microvascular compli-
cations (Klein 1995b; Laakso 1999).
Hyperinsulinaemia / insulin resistance:
Hyperinsulinaemia could influence atherogenesis
both by direct action on arterial wall and indi-
rectly through other components of the metabolic
syndrome. In animal studies high insulin con-
centrations  stimulated cholesterol synthesis and
binding of LDL cholesterol to smooth muscle
cells and macrophages in the arterial wall (Stout
1990). Hyperinsulinaemia has predicted CHD
events in non-diabetic men (Welborn et al. 1979;
Ducimetière et al. 1980; Pyörälä et al. 1998).
There are also data supporting an association
between hyperinsulinaemia and CHD risk in type
2 diabetes (Rönnemaa et al. 1991, Hanefeld et
al. 1997). Hyperinsulinaemia has generally been
considered as a marker of insulin resistance; a
decrease in the effect of insulin to stimulate glu-
cose uptake at a given insulin concentration. The
golden standard for the measurement of insulin
Chronic diabetic complications
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sensitivity / resistance is the euglycaemic
hyperinsulinaemic clamp technique (Ferrannini
1998). As this technique is time-consuming and
expensive the use has been limited to clinical
research centres. Other methods to assess insu-
lin resistance have been the homeostasis model
assessment (HOMA), using fasting insulin and
fasting plasma glucose concentrations ( Matthews
et al. 1985), the frequently-sampled intravenous
glucose tolerance test (FSIGT) (Haffner et al.
1997) and fasting insulin concentration (Laakso
1993).
Reaven introduced the term Syndrome X in
1988 and suggested that insulin resistance and
compensatory hyperinsulinaemia underlie the
clustering of cardiovascular risk factors such as
glucose intolerance, hypertension and
dyslipidaemia (Reaven 1988). This clustering of
cardiovascular risk factors has been suggested
as possible mechanism for the increased risk of
CVD in type 2 diabetes. In a recent Finnish study
clustering of a high BMI, high triglycerides, low
HDL cholesterol and endogenous
hyperinsulinaemia predicted cardiovascular mor-
tality in patients with type 2 diabetes (Lehto S et
al. 2000).
Dyslipidaemia: In type 2 diabetes lipid ab-
normalities are almost the rule. Typical findings
are elevation of total and VLDL triglyceride con-
centrations, exaggerated postprandial lipaemia,
lowering of HDL cholesterol and a predominance
of small, dense LDL particles (Taskinen et al.
1996).  Insulin resistance is often involved in
this process (Syvänne et al. 1997).
Hypertriglyceridaemia has been associated with
increased risk of CHD both in non-diabetic
(Hokanson et al. 1996) and type 2 diabetic sub-
jects (Fontbonne et al. 1989). Remnants of trig-
lyceride-rich lipoproteins seem to be extremely
atherogenic (Zilversmit 1995; Karpe et al. 1995).
The LDL particle size pattern can be classi-
fied by use of gradient gel electrophoresis (Aus-
tin et al. 1988). Pattern A is characterised by a
predominance of large buoyant LDL particles
(>25.5 nm), whereas pattern B is the phenotype
with a predominance of small LDL particles,
which has been associated with CHD (Stampfer
et al. 1996; Gardner et al. 1996; Lamarche et
al.1997). The LDL particle size is both geneti-
cally determined and related to lifestyle factors
such as diet and exercise (Lamarche 1999). Small
dense LDL particles have been associated with
the individual components of the metabolic syn-
drome (Haffner 1995; Austin 1996). The
proatherogenic properties of small LDL particles
may relate to their ability to penetrate the arte-
rial wall and thereby making them more suscep-
tible to oxidation (Hurt-Camejo et al. 1992).
Figure 5. Age-adjusted cardiovascular death rate (per 10.000 
person years) by number of risk factors in patients with and 
without diabetes in MRFIT (Stamler et al. 1993)
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Elevated LDL cholesterol has also been as-
sociated with CHD in follow-up studies (Turner
et al. 1998; Forsblom et al. 1998b). Elevated LDL
cholesterol predicted CHD in patients without
macroangiopathy at baseline indicating that el-
evated LDL cholesterol becomes important after
exclusion of high-risk patients with CHD at base-
line. In patients with macroangiopathy at base-
line the features of the metabolic syndrome seem
to be the strongest predictor of death (Forsblom
et al. 1998b).
Impaired fibrinolysis and increased coagu-
lability: An imbalance in the haemostatic sys-
tem due to hypercoagulability or impaired fibri-
nolytic function may favour the development of
vascular damage and can be involved in the
atherosclerotic plaque rupture. Plasminogen ac-
tivator inhibitor type 1 (PAI-1) is a potent in-
hibitor of fibrinolysis. Increased levels of PAI-1
have been demonstrated in survivors of acute
myocardial infarction and in patients with coro-
nary artery stenosis (Hamsten et al. 1985). Epi-
demiological studies have suggested links be-
tween PAI-1 and the components of the meta-
bolic syndrome (Juhan-Vague et al. 1993).
There are also studies indicating that fibrino-
gen levels are elevated in patients with diabetes
and CHD. Raised fibrinogen concentrations fa-
vour coagulation and increase platelet activation
and adherence to the endothelium (Ernst et al.
1993). Increased levels of von Willebrand factor
(Chen et al. 1995) and lipoprotein (a) have also
been reported in diabetic subjects (Heller et al.
1993).
Microalbuminuria: Microalbuminuria and
albuminuria are markers of increased cardiovas-
cular risk in both type 1 and type 2 diabetic sub-
jects. In addition to being a sign of incipient re-
nal damage, microalbuminuria has been sug-
gested as a marker of endothelial damage and
increased transcapillary albumin leakage
(Deckert et al. 1989; Jensen et al. 1995). In type
2 diabetic patients microalbuminuria is a strong
predictor of cardiovascular morbidity and mor-
tality (Kuusisto et al. 1995; Jensen et al. 1997;
Dinneen et al. 1997; Borch-Johnsen et al. 1999).
In type 1 diabetes microalbuminuria has also been
linked to CVD due to its possible association with
other cardiovascular risk factors such as
dyslipidaemia (Groop et al. 1993) and hyperten-
sion (Mathiesen et al. 1995). In type 2 diabetes
microalbuminuria has been associated with in-
sulin resistance and the components of the insu-
lin resistance or metabolic syndrome (Groop et
al.1993; Kuusisto et al. 1995).
Other risk factors: Although physical inac-
tivity predicts CVD in non-diabetic individuals
(Blair et al. 1996), data on diabetic patients are
limited. In a recently published study a low level
of cardiorespiratory fitness and physical inactiv-
ity was associated with increased CVD mortal-
ity in men with type 2 diabetes (Wei et al. 2000).
Obesity, a very common feature in type 2 dia-
betic patients, has not independently been asso-
ciated with cardiovascular diasese in diabetic
patients (Laakso 2001).
Chronic diabetic complications
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Aims of the study
The aims of this study were to evaluate the following:
1. The prevalence of chronic diabetic complications in patients with maturity-onset diabetes in
the young (MODY3) from five large Finnish families (I).
2. The prevalence of chronic diabetic complications in patients with slowly progressing
autoimmune type 1 diabetes (LADA) and compare them to findings in type 1 and type 2
diabetic patients from the same region (II).
3. The prevalence of the metabolic syndrome and its components and to study the
cardiovascular morbidity and mortality associated with the metabolic syndrome (III).
4. The impact of different features of the metabolic syndrome on chronic diabetic
complications in patients with type 2 diabetes (IV).
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Subjects and study design
The characteristics of the patients included
in the studies are shown in Table 8. The patients
with MODY3 diabetes (Study I), patients with
slowly progressing autoimmune type 1 diabetes
(LADA) and their controls (Study II) as well as
the patients with and without the metabolic syn-
drome (Study IV) were recruited from the Botnia
Study in western Finland. The Botnia Study rep-
resents a large family study in Finland and Swe-
den that was initiated in 1990 with the aim to
identify early metabolic defects in families with
type 2 diabetes (Groop et al.1996a). Type 1 dia-
betic patients, were recruited as consecutive pa-
tients from the outpatient clinic of Jakobstad
Hospital, Jakobstad, Finland. Type 1 diabetes was
defined as onset of diabetes before the age of 35,
a history of ketoacidosis and immediate need of
insulin treatment. In addition, for the ophthal-
mologic comparison in study I, data from
Helsingborg, Sweden (38 patients with type 1 and
38 with type 2 diabetes) were used.
All subjects gave their informed consent be-
fore entering the studies, and the study protocols
of the Botnia Study have been approved by local
Ethics Committees.
 1. Chronic diabetic complica-
tions in patients with MODY3
diabetes (I)
57 patients with MODY3 diabetes from 5
large Finnish families were examined for the
presence of diabetic complications. Forty-nine
patients from four families shared the same in-
sertion mutation of exon 4 in the HNF-1α gene
whereas eight  patients from the fifth family had
a missense mutation in the HNF-1α gene (Lehto
M et al. 1997). The clinical characteristics of the
MODY3 patients and  type 1  (N=111) and type
2 (N=159) diabetic patients matched for dura-
tion of diabetes and glycaemic control are shown
in Table 8. The prevalence of diabetic complica-
tions in patients with MODY3 diabetes was  com-
pared between the three groups. By use of multi-
ple logistic regression analysis risk factors for
diabetic complications were analysed.
2. Chronic complications in
patients with slowly progressing
autoimmune type 1 diabetes
(LADA) (II)
The LADA patients were recruited from the
Botnia study in Western Finland (Groop et al.
1996a). Of 1122 patients given a diagnosis of
type 2 diabetes, 104 (9.3%) were positive for
GADA (Tuomi et al. 1999). Among them we
identified 90 GADA positive patients who at
onset of diabetes were over 35 years old and had
no signs of ketoacidosis. 16 patients (18%) had
died since their first participation in the Botnia
study, and 15 patients were not available for ex-
amination. The remaining 59 LADA patients
were examined for the presence of diabetic com-
plications and compared with 59 GADA nega-
tive type 2 diabetic patients from the Botnia study,
matched for age, sex and duration of diabetes
with the LADA patients. The findings in the
LADA patients were also compared with type 1
diabetic patients (n=111) representing consecu-
tive patients from the outpatient clinic of the
Jakobstad Hospital (Jakobstad, Finland).
3. Cardiovascular morbidity
and mortality associated with
the metabolic syndrome (III)
From a total of 6645 persons participating in
the Botnia study all subjects aged 35-70 years
(n=4483) were included in this study. Patients
28
with GADA (Tuomi et al.1999) and MODY veri-
fied by DNA analysis (Lehto M et al. 1997), were
excluded.
Glucose tolerance was assessed according to
the new ADA/WHO criteria using a 75 g oral
glucose tolerance test (OGTT) (Alberti et al.
1998). Of the subjects studied 1697 had diabe-
tes, 798 had abnormal glucose tolerance, which
included both impaired fasting glucose (IFG) and
IGT whereas 1988 subjects had a normal glu-
cose tolerance (NGT). For the definition of the
metabolic syndrome the WHO proposal from
1998 was used (Alberti et al. 1998) (Table 3).
The prevalence of the metabolic syndrome and
the components of the syndrome and the associ-
ated cardiovascular risk were assessed in the dif-
ferent groups of glucose tolerance.
Total and cardiovascular mortality was as-
sessed in 3606 subjects from the original Botnia
centres in western Finland with a median fol-
low-up of 6.9 years. Mortality data were obtained
from a central death-certificate registry.
4. The impact of different fea-
tures of the metabolic syndrome
on chronic complications in type
2 diabetes (IV)
The diabetic patients were recruited from the
Botnia Study. We studied a random sample of 85
patients who fulfilled the criteria for the meta-
bolic syndrome (Alberti et al. 1998) and com-
pared them to 85 patients, matched for age, sex
and duration of diabetes, who did not fulfil the
criteria for the syndrome. The definition of the
metabolic syndrome was modified regarding the
criteria for central obesity (cutoff for WHR: >1.0
in males; >0.9 in females) according to the dis-
tribution of obesity in a Scandinavian popula-
tion (Study III). Patients with MODY were ex-
cluded by genetic characterisation (Lehto M et
al. 1997). Patients with GADA were also ex-
cluded (Tuomi et al. 1999). Risk factors for dia-
betic complications were analysed by multiple
logistic regression analysis.
Table 8 : Characteristics of subjects included in the studies. 
 
Study Patients Number (M/F) Age 
(years) 
Duration 
(years) 
HbA1cb 
(%) 
Design 
I MODY3 
Type 1 DM 
Type 2 DM 
Type 1 DMa 
Type 2 DMa 
57 (29/28) 
111 (67/44) 
159 (63/96) 
38 (20/18) 
38 (25/13) 
44±16 
39±12 
69±12 
34±13 
59±12 
17±13 
23±12 
23±6 
16±13 
15±12 
7.3±1.6 
7.7±1.5 
7.6±1.9 
6.9±1.3 
7.1±1.3 
cross-
sectional 
II LADA 
Type 1 DM 
Type 2 DM 
59 (26/33) 
111 (67/44) 
59 (26/33) 
70±11 
39±12 
69±10 
13±6 
23±12 
12±6 
8.3±1.5 
8.8±1.5 
8.2±1.4 
cross-
sectional 
III NGT 
IGT 
Type 2 DM 
1988 (1133/855) 
798 (397/401) 
1697 (804/893) 
50±10 
53±10 
59±8 
NA 
NA 
8±7 
ND 
ND 
8.0±1.6 
cross-
sectional, 
prospective 
IV MSDR+ 
MSDR- 
85 (53/32) 
85 (53/32) 
59±9 
61±7 
8±6 
9±6 
7.9±1.6 
7.5±1.4 
cross-
sectional 
NA: not applicable, ND: not done. a Patients  (Helsingborg, Sweden) for the ophthalomologic comparison, 
matched with the MODY3 patients for duration and HbA1c. b HbA1c was measured by a method with lower 
reference values (Kyoto Daichii, Kyoto, Japan) in study I, whereas an other method (Diamat, Hercules, CA) was 
used in the other studies.  
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Methods
1. Assessment of diabetic com-
plications
Retinopathy: The diagnosis of retinopathy
was based upon fundus photography. Colour fun-
dus photographs were obtained after pharmaco-
logical mydriasis at an angle of 45-60 degrees
with a Topcon TRC NW5 fundus camera (Topcon
Optical Co. Ltd, Tokyo, Japan) or a Canon CF-
60U fundus camera (Canon, Tokyo, Japan). The
photographs covered fields 1-3 of the seven stand-
ard fields, with stereo pairs of the macula (field
2). The alternative classification of the Wiscon-
sin Epidemiological Study of Diabetic Retinopa-
thy was used to define the retinopathy level (Klein
et al. 1986).
The patient´s retinopathy level was derived
by giving the eye with the higher level a greater
weight (Table 9). This scheme provides an 11-
step scale: 10/10, 21/10, 21/21, 31/<31, 31/31,
41/<41, 41/41, 51/<51, 51/51, 60+/<60+, 60+/
60+. Based upon this scale the retinopathy lev-
els of the patients were divided into 4 groups; no
DR (level 10/10), mild DR (levels 21/10 - 31/
31), moderate DR (levels 41/<41 - 51/<51), and
severe NPDR or PDR (level 51/51 - 60+/60+).
Macular oedema was defined as presence of
hard exudates and/or retinal thickening within
one disc diameter of the centre of the macula
and was considered present if at least one eye
was affected.
Photographs were viewed against light boards
using Donaldson´s stereo viewer (5x magnifica-
tion) and assessed by an independent grader. In
the type 1 diabetic patients (n=111) the classifi-
cation of retinopathy was based upon photogra-
phy (n=62) or clinical data from hospital records.
Two blind MODY3 patients (study I) were ex-
cluded from photography because of media opaci-
ties. In study IV the classification of retinopathy
was based upon (ophthalmologic) hospital
records in 3 patients and on ophthalmoscopy in
one patient.
Nephropathy and microalbuminuria:
Microalbuminuria was considered to be present
if AER in overnight urine exceeded 20 µg/min
and macroalbuminuria if AER exceeded 200 µg/
min (Mogensen et al. 1995). Overnight urine was
not available in 8% and 6%, respectively, of the
patients in study II and IV and the albumin-to-
creatinine ratio (ACR) in the morning urine was
used. An ACR exceeding 2.5 mg/mmol in males
and 3.5 mg/mmol in females was considered as
abnormal (Mogensen et al. 1995). In study III
urine for the measurement of AER was collected
either during the OGTT (n=1082) or overnight
(n=1579). AER measured overnight correlated
with AER during OGTT (r=0.605, p<0.001; N
= 442).
In study IV two patients who fulfilled other
criteria of the metabolic syndrome had chronic
glomerulonephritis of non-diabetic origin and
were excluded from the analysis of nephropathy.
Neuropathy: The diagnosis of distal sensory
Table 9: Grading of retinopathy. 
 
Level Characteristic findings 
10 no diabetic retinopathy  
21 microaneurysms only or blot haemorrhages 
or soft exudates in the absence of 
microaneurysms 
31 hard exudates or mild retinal haemorrhages 
41 soft exudates or intraretinal microvascular 
abnormalities (IRMA) 
51 severe retinal haemorrhages or IRMA or 
venous bending in at least one field 
60+ all levels of PDR, with or without laser 
treatment 
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neuropathy was based upon a clinical examina-
tion and a symptom score (Young et al. 1993).
The clinical examination consisted of meas-
urements of:
1) achilles tendon reflexes graded 0-2 for each
side (normal=0, present with reinforcement = 1
and absent = 2), giving a maximum score of 4 if
both sides were affected,
2) vibration sensation by a 128 Hz vibration
fork at the hallux, graded 0-1 for each side (nor-
mal = 0, absent = 1) giving a maximum score of
2,
3) sensory perception by a 10 g Semmes-
Weinstein monofilament at three sites on each
foot, graded 0 -2 for each side (normal = 0, ab-
sent on one site = 1, absent on 2 or 3 sites = 2 )
giving a maximum score of 4.
The maximum score for the clinical exami-
nation was 10. A score of 3-5 was regarded as
evidence for mild signs, a score of 6-8 for mod-
erate signs and a score of 9-10 for severe signs
of distal neuropathy. The clinical examination
was performed by one examiner (B.I.).
For the subjective symptom score the patient
answered a questionnaire (Young et al. 1993). If
the patient described burning, numbness or tin-
gling a score of 2 was assigned; fatigue, cramp-
ing or aching was scored 1. The presence of
symptoms in the feet was assigned a score of 2,
in the calves 1 and elsewhere a score of 0. Noc-
turnal exacerbation of symptoms scored 2 vs 1
for both day and night and 0 for daytime only. A
score of 1 was added if the symptoms had woken
the patient from sleep. The patients were asked
which manoeuvre reduced the symptoms: walk-
ing was assigned a score of 2, standing of 1 and
lying down was scored 0. A symptom score of 3-
4 indicated mild symptoms, a score of 5-6 mod-
erate and a score of 7-9 severe symptoms of distal
neuropathy. The minimum criteria for the diag-
nosis of distal sensory neuropathy were moder-
ate signs with or without symptoms or mild signs
with moderate symptoms.
In study I and II neuropathy was also assessed
by measuring the vibration threshold at the an-
kle with a Biothesiometer (Biomedical Instru-
ments, Ohio, USA). As control, vibration per-
ception threshold was also measured in 58 per-
sons with NGT and without clinical signs or
symptoms of neuropathy. An age-correlated
threshold was calculated and a value exceeding
2 SD above the mean was considered abnormal.
There was a strong positive correlation between
the Biothesiometer measurements and the clini-
cal neuropathy score (r=0.82; p<0.0001, N=36,
Study I: MODY3 patients), while there was a
weaker correlation between the Biothesiometer
measurements and the subjective symptom score
(r=0.49, p=0.003, N=36).
In study IV the vibration perception thresh-
old at the ankle was assessed with a Vibrameter
(Somatomedic productions AB, Sollentuna, Swe-
den) in 138 of the patients (68 with and 76 with-
out the metabolic syndrome). As control, the vi-
bration perception threshold was also measured
in 45 subjects aged 35-70 years with NGT and
no clinical signs of neuropathy. The vibration
perception correlated to height and therefore a
height-adjusted threshold was calculated and a
value exceeding 3.3 µm (corresponding to the
95th percentile) was considered abnormal. In the
type 2 diabetic patients the height-adjusted vi-
bration threshold correlated with the score from
the neurological examination (r=0.49, p<0.001,
n=138) but not with the symptom score (r=-0.01,
p=0.92, n=138).
Coronary heart disease: In study I, II and
IV a history of myocardial infarction or stroke
was based upon information in hospital records.
Also, a diagnosis of CHD was based upon hospi-
tal records or use of nitroglycerine and patho-
logical findings in resting electrocardiogram
(ECG). The ECGs were coded using the Minne-
sota codes 1.1-3, 4.1-4, 5.1-3 (Rose et al. 1968)
by one examiner (B.I.). In study III a standard-
ised health questionnaire was completed by spe-
cially trained nurses. CHD was defined as use of
nitroglycerine or typical chest pain or a history
of previous myocardial infarction. This informa-
tion was validated against ECG changes accord-
ing to the Minnesota code compatible with
ischaemic heart disease  (Rose et al. 1968) in all
subjects from one of the centres (N=555).  Myo-
cardial infarction, defined in accordance with the
WHO MONICA criteria (Tunstall-Pedoe et al.
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1994) and stroke (including both ischemic and
haemorrhagic stroke) were defined as events re-
quiring hospitalisation; this information was
verified from local hospital records.
Peripheral vascular disease: The diagnosis
of peripheral vascular disease was based upon
hospital records, palpation of foot pulses, clini-
cal symptoms of claudication and measurement
of ABI. Ankle systolic pressure was measured
after 5 min. of rest in the supine position using a
Doppler device (Multi-Doplex II, Huntleigh
Technology, Cardiff, UK). A standard blood pres-
sure cuff was placed around the right ankle and
the blood flow in the posterior tibial artery was
registered. The mean from two measurements
was used and related to the auscultatory meas-
urement of  systolic pressure in the right arm.
An ABI less than 0.9 was considered diagnostic
for peripheral vascular disease (Leng et al. 1996).
2. Assessment of mortality
In Study II total and cardiovascular mortal-
ity was assessed in 90 GADA-positive patients
and 929 type 2 diabetic patients during a me-
dian follow-up of 5.7 years. In study III total and
cardiovascular mortality was assessed in 3606
subjects from the original Botnia centres in west-
ern Finland with a median follow-up of 6.9 years.
Mortality data were obtained from a central
death-certificate registry. Cardiovascular mortal-
ity was classified using the ninth revision of the
International Classification of Diseases (ICD-9,
cardiovascular diagnosis codes 390-459) before
1997 and ICD-10 (codes I 00 -I 99) thereafter.
3. Assessment of glucose tole-
rance
The diagnosis of diabetes was either based
upon use of antidiabetic medication or existing
criteria. In Study I the diagnosis of diabetes was
based on the WHO criteria (WHO 1985) and in
the other studies the new ADA/WHO criteria
(Alberti et al. 1998). Thus, subjects with a fast-
ing plasma glucose ≥7.0 mmol/l and/or 2-h
plasma glucose ≥11.1 mmol/l during an OGTT
were considered to have diabetes, subjects with
a fasting plasma glucose 6.1-6.9 mmol/l and/or
a 2-h plasma glucose 7.8 -11.0 mmol/l were con-
sidered to have abnormal glucose tolerance,
which included both IFG and IGT. The glucose
tolerance was considered normal (NGT) if fast-
ing plasma glucose was <6.1 mmol/l and 2-h glu-
cose <7.8 mmol/l.
4. Anthropometric measure-
ments and blood pressure
Body weight and height were measured with
subjects in light clothing without shoes and body
mass index (BMI) was calculated. Waist circum-
ference was measured with a soft tape on stand-
ing subjects midway between the lowest rib and
the iliac crest. Hip circumference was measured
over the widest part of the gluteal region, and
waist-to-hip ratio (WHR) as a measure of cen-
tral obesity was calculated. Two blood pressure
recordings were obtained from the right arm of a
sitting person after 30 min of rest at 5-min inter-
vals, and their mean value was calculated. In
study I and II hypertension was considered
present if the patient used antihypertensive drugs
or had a blood pressure over 160/95 mmHg. In
study III and IV the cutoff for the blood pressure
was 160/90 according to the WHO proposal for
the definition of the metabolic syndrome (Alberti
et al. 1998).
5. Assays
Plasma glucose was measured with a glu-
cose oxidase method using a Beckman Glucose
Analyzer II (Beckman Instruments, Fullerton,
CA). Serum insulin  concentrations
were measured with radioimmunoassay
(Pharmacia&Upjohn, Uppsala, Sweden) with an
interassay coefficient of variation (CV) of 5 %.
Fasting serum C-peptide concentrations were
measured by a radioimmunoassay (Linco Re-
search, St. Charles, MO, USA) with an interassay
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CV of 9%.
GAD antibodies were determined by a modi-
fied radiobinding assay using 35 S-labeled
recombinant human GAD65 (Tuomi et al. 1999).
The antibody titre is expressed in relative units
(RU). The cut-off limit for positivity was set at 5
RU, which represents the mean +3 SD of 296
Finnish healthy control subjects.
Lipids and lipoproteins: Serum total cho-
lesterol, HDL cholesterol subfractions (after pre-
cipitation), and triglyceride concentrations were
measured on a Cobas Mira analyser (Hoffman
LaRoche, Basel, Switzerland). The LDL choles-
terol concentrations were calculated using the
Friedewald formula (Friedewald et al. 1972). The
formula was not used if serum triglyceride con-
centration exceeded 4.0 mmol/l. Apolipoprotein
A-I and A-II were determined with
immunoturbidimetric methods using commer-
cially available kits (Boehringer Mannheim,
Mannheim, Germany), while apolipoprotein B
concentration was measured by an
immunochemical assay (Orion Diagnostica,
Espoo, Finland). The interassay CV for
apolipoprotein A-I, A-II and B were 3.6, 2.1 and
4.9 %, respectively.
LDL particle size: The LDL particle size
(study IV) was determined by electrophoresis on
gradient polyacrylamide gel (Lahdenperä et al.
1995). The particle size of two isolated LDL sam-
ples were used as reference, and their size was
measured by electron microscopy. The calculated
mean diameters of LDL standards were 27.9 and
23.9 nm. The mean particle diameter of the ma-
jor LDL peak was determined by comparing the
mobility of the sample to the mobility of the cali-
brated LDL preparation run on each gel. The CV
for the intergel precision of the control sample
that was used, was 1.4 %. Small LDL particles
were defined as a particle size smaller than 25.5
nm (Austin et al. 1988).
Urinary albumin concentration was meas-
ured by radioimmunoassay (Pharmacia&Upjohn,
Uppsala, Sweden) with a detection limit of 2 mg/
l and an interassay CV of 5 %.
Estimation of insulin resistance: In study
III we applied the Homeostasis Model Assess-
ment (HOMA) to obtain an estimate of insulin
resistance. The following formula was used: in-
sulin resistance (HOMA-IR) = fasting insulin
(µU/ml) x fasting plasma glucose (mmol/l) / 22.5
(Matthews et al. 1985) In the Botnia study the
HOMA-IR correlated inversely with insulin sen-
sitivity measured during a euglycaemic
hyperinsulinaemic clamp in 35-70 year old non-
diabetic subjects (r=-0.46, p<0.001, n=132).
Glycaemic control: In study I HbA1c was de-
termined by a high-pressure liquid chromatog-
raphy method (Kyoto Daichii, Kyoto, Japan) with
a reference value < 5.5%. In study II and IV
HbA1c concentrations were measured by high-
performance liquid chromatography (Diamat,
Hercules, CA, USA) with a reference value for
the method of 4-6 %. The most recent measure-
ment of HbA1c correlated strongly with the val-
ues measured during the last 5 years (MODY3
patients: r=0.91, p<0.001, n=23; LADA patients:
r=0.78, p<0.001, n=49) and in study I and II the
last HbA1c value was used as a measure of gly-
caemic control in the analysis. In study IV the
mean of HbA1c measurements done during the
last 5 years (median 4 measurements, range 1-
18) was used as a measure of glycaemic control.
6. Statistical analysis
The values are presented as means ±SD, or
as median and range (Study II) or percentages.
The significance of differences between group
means has been tested with t-test or one-way
analysis of variance after logarithmic transfor-
mation of variables not showing a normal distri-
bution or with the Mann-Whitney U-test (study
I). Adjustments for age and BMI have been done
where appropriate. Differences between group
frequencies were tested with Chi-squared or
Fisher´s exact test. Correlations were tested us-
ing the Spearman rank correlation coefficients.
The relationship between dependent variables,
such as neuropathy, retinopathy,
microalbuminuria, CHD and cardiovascular
mortality, and independent variables were tested
with multiple logistic regression analysis using
an SPSS program for Windows. In study III a
multiple logistic regression analysis was carried
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out with CHD, previous myocardial infarction
or stroke as dependent variable and age, sex and
the metabolic syndrome or its components as in-
dependent variables. In all analyses of diabetic
complications (study I, II and IV) we used HbA1c
and duration of diabetes as continuous variables
and male sex as categorical variable. A p-value
less than 0.05 was considered statistically sig-
nificant.
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Results
1. Complications in patients
with MODY3 diabetes (I)
The MODY3 patients are compared with type
1 and type 2 diabetic patients in Table 10. Twenty
(53%) of the 38 MODY3 patients who took part
in the ophthalmological examination had no
signs of retinopathy, 13 (34%) had mild NPDR
and 5 patients (13%) had severe NPDR or PDR.
There was no significant difference in the preva-
lence of retinopathy among MODY3 and type 1
and type 2 diabetic patients matched for dura-
tion of diabetes and glycaemic control.
Distal neuropathy was found in 29% of the
MODY3 patients compared to 13% in the type 1
diabetic patients (p<0.001). The prevalence of
microalbuminuria was 19% in the MODY3 pa-
tients, which did not differ from the prevalence
in type 1 and type 2 diabetic patients (24 and
23%). Four MODY3 patients had
macroalbuminuria and one was being treated for
uraemia. The prevalence of hypertension was
similar in MODY3 and type 1 diabetic patients
(24.5 % vs 19 %), but lower than in type 2 dia-
betic patients (53.7%, p<0.001).
Coronary heart disease was more often seen
in MODY3 than in type 1 diabetic patients (16
vs 4.5%), but less frequently than in the older
type 2 diabetic patients (16 vs 33.3 %). One of
the MODY 3 patients had a history of ischemic
stroke with a persisting defect in visual fields.
None of the MODY3 patients had signs of pe-
ripheral vascular disease, i.e. ABI was higher
than 0.9 in all patients.
In a multiple logistic regression analysis with
the different diabetic complications as depend-
ent variables, poor glycaemic control was asso-
ciated with retinopathy (RR 3.1, p=0.03),
microalbuminuria (RR 2.3, p=0.04) and elevated
vibration threshold (RR 5.0, p=0.03)(Table 11).
Table 10: Comparison between MODY3, type 1 and type 2 diabetic patients.  
 
 
MODY3 
 
Type 1 DM 
 
Type 2 DM 
 
Number (M/F) 57 (29/28) 111 (67/44) 159 (63/96) 
Age (years) 43.7 ± 15.7 38.6 ± 12.5 69.4 ± 11.6** 
Duration  (years) 17. ± 12.8 23.1 ± 12.0 22.9 ± 6.1 
BMI (kg/m2) 24.6 ± 4.5 25.1 ± 3.2 27.5 ± 4.9** 
WHR 0.89 ± 0.08 ND 0.93 ± 0.08 
HbA1c (%) 7.3 ± 1.6 7.7 ± 1.5  7.6 ± 1.9 
Cholesterol (mmol/l) 5.3 ± 1.0 5.0 ± 0.9 5.9 ± 1.3* 
HDL cholesterol (mmol/l) 1.40 ± 0.21 1.45 ± 0.40 1.25 ± 0.40* 
Triglycerides (mmol/l) 1.53 ± 0.82++ 1.01 ± 0.50 1.86 ± 1.04* 
AER > 20 µg/min (%) 19 24 23 
Hypertension (%) 24 19 54** 
Diabetes therapy    
- Diet alone (%) 33 0 60.3 
- Oral agents (%) 30 0 31.5 
- Insulin (%) 37 100 8.2 
Coronary heart disease (%) 16+ 4.5 33+ 
Values are mean ± SD, ND: not done ; *p< 0.01, **p<0.001 vs MODY or IDDM; +p<0.02, ++p<0.001 vs IDDM. 
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Table 11: The relative risk of diabetic complications associated with 1 % 
increase in HbA1c in MODY3 patients. 
Complication RR (95% CI) p-value 
Retinopathy 3.1 (1.1 – 8.6) 0.03 
Microalbuminuria 2.3 (1.05 – 5.0) 0.04 
Elevated vibration threshold  5.0 (1.15 – 22.1) 0.04 
 
Results
Table 12. Clinical characteristics of type 2, LADA and type 1 diabetic patients 
           
 Type 2  
diabetes 
LADA Type 1  
diabetes 
Number (M/F)  59 (26 / 33) 59 (26 / 33) 111 (67 / 44) 
Age ( years) 72 (12) 74 (12) 39 (20)‡ 
Duration (years) 12 (10) 13 (9) 22 (16)‡ 
BMI ( kg/ m2 ) 28 (6.0) 27.8 (6.3)* 24.5 (3.6)¶ 
WHR - male 1.00 (0.09) 0.96 (0.12)* ND 
WHR - female 0.90 (0.12) 0.87 (0.09)* ND 
C-peptide ( nmol/l ) 0.76 (0.43) 0.45 (0.71)† ND 
C-peptide < 0.3 nmol/l (%) 3 32† ND 
HbA1c ( % ) 8.4 (2.3) 8.2 (2.3) 8.5 (1.9) 
Hypertension (%) 75 58* 21‡ 
Cholesterol ( mmol/l )  5.5 (1.1) 5.5 (1.3) 4.8 (1.3) 
LDL cholesterol ( mmol/l ) 3.5 (1.1) 3.4 (1.2) 3.0 (1.1) 
HDL cholesterol ( mmol/l ) 1.19 (0.33) 1.20 (0.46) 1.41 (0.59)¶ 
HDL2 cholesterol ( mmol/l ) 0.35 (0.20) 0.43 (0.30)* ND 
HDL3 cholesterol (mmol/l) 0.84 (0.14) 0.79 (0.24) ND 
Triglycerides ( mmol/l ) 1.45 (0.70) 1.29 (0.64) 0.90 (0.60)¶ 
Diabetes therapy      
 - Diet alone ( % ) 20 19 0 
 - Oral agents ( % ) 36 27 0 
 - Oral agents and insulin (%)  42 14† 0 
 - Insulin ( % )  3 39† 100‡ 
Values are median (interquartile range). ND: not done. BMI, cholesterol, LDL and HDL cholesterol 
and triglycerides were adjusted for age before comparison between groups. * p<0.05 vs type 2 
diabetes, † p<0.001 vs type 2 diabetes, ‡ p<0.001 vs type 2 diabetes or LADA,  ¶ p<0.05 vs type 2 
diabetes. 
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Duration of diabetes was associated with retin-
opathy (RR 1.13, p=0.03) and male sex with el-
evated vibration threshold (RR 6.7, p=0.04).
2. Complications in patients
with slowly progressing
autoimmune type 1 diabetes
(LADA) (II)
The LADA patients had lower BMI (p=0.04),
WHR (p=0.02 for men and p=0.03 for women),
and fasting C-peptide concentrations (p<0.001)
and higher HDL2 concentrations (p=0.04) and
less hypertension (58 vs 75 %, p=0.05) than the
type 2 diabetic patients (Table 12).
The prevalence of retinopathy (51 vs 56 %),
microalbuminuria (27 vs 29 %), neuropathy (29
vs 27 %) and CHD (58 vs 56 %) did not differ
between the LADA and the type 2 diabetic pa-
tients (Figure 6). The type 1 diabetic patients had
lower prevalence of neuropathy (13 %, p=0.02)
and CHD (4.5 %, p<0.001) and higher preva-
lence of retinopathy (76%, p<0.001) compared
to the other groups. In a logistic regression analy-
sis with moderate or severe retinopathy as the
dependent variable, both duration of diabetes (RR
1.18, p=0.01) and HbA1c (RR 1.88, p=0.03) were
associated with retinopathy in the LADA but not
in the type 2 diabetic patients.
Mortality data were obtained from the LADA
and type 2 diabetic patients after a median fol-
low-up period of 5.7 years. During this time 16
of the 90 LADA patients (18%) had died, com-
pared to 186 of 929 type 2 diabetic patients (20%).
Cardiovascular mortality was slightly lower in
the LADA than in the type 2 diabetic patients
(7.4 vs 12.4 %, p=0.2).
In a logistic regression analysis HbA1c (RR
1.78, p=0.02) was significantly associated with
CHD in LADA, while age (RR 1.09, p=0.02) and
male sex (RR 7.55, p=0.006) were independent
risk factors for CHD in the type 2 diabetic pa-
tients.
3. Cardiovascular morbidity
and mortality associated with
the metabolic syndrome (III)
The data from 4483 patients (NGT n=1988,
IFG/IGT n=798, type 2 DM n=1697) aged 35 -
70 years were used to study the prevalence of the
metabolic syndrome and its components and the
cardiovascular risk associated with the metabolic
syndrome. The prevalence of the metabolic syn-
drome and its components are shown in Table
13. The prevalence of obesity was high in all
groups, especially in males; 76 % of men with
NGT and 92% of diabetic men fulfilled the cri-
teria for obesity.
The prevalence of dyslipidaemia and hyper-
tension were both 2-fold increased in type 2 dia-
betic patients compared to subjects with NGT.
The prevalence of microalbuminuria was low in
subjects with NGT and IFG/IGT (3-7%), while
22 % of the diabetic men and 12% of the dia-
betic women had microalbuminuria; in most sub-
jects it was also associated with hypertension.
The prevalence of insulin resistance, defined
as the highest quartile of HOMA-IR, was 2-fold
increased in subjects with IFG/IGT and 3-fold
increased in patients with type 2 diabetes com-
pared with subjects with NGT. In women with
NGT the prevalence of insulin resistance in-
creased from 19 % in the age-decade 40-49 year
to 35 % in the age-decade 60-69 year (p<0.001).
Using the proposed WHO criteria the preva-
lence of the metabolic syndrome was more com-
mon in non-diabetic males than in females, i.e.
Figure 6. Prevalence (%) of complications in 
LADA, type 2 and type 1 diabetic patients.
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15 and 10%, respectively, in subjects with NGT,
and 64 and 42%, respectively, in subjects with
IFG/IGT (Fig. 7). The sex-specific difference was
almost abolished in the type 2 diabetic patients,
i.e. 84% and 78%, respectively. In women with
NGT the prevalence of the metabolic syndrome
increased from 6 % in the youngest (40-49y) to
19 % in the oldest (60-69 y) age-decade
(p<0.001).
Cardiovascular disease in relation to the
metabolic syndrome: The lowest prevalence of
CHD was seen in NGT subjects without the meta-
bolic syndrome and the highest in type 2 dia-
betic patients with the metabolic syndrome (4.1%
vs 27.1 %, p<0.001) (Fig. 8). In all subjects CHD,
a history of myocardial infarction and stroke was
more common in subjects with than without the
metabolic syndrome (p<0.001) (Fig. 9). In a sub-
set of 555 patients in whom the presence of CHD
could be based on Minnesota coding of ECG in
addition to clinical data, the prevalence of CHD
was even further increased in patients with the
metabolic syndrome (35 % vs 8 %, p<0.001).
Cardiovascular risk in relation to the meta-
bolic syndrome and its components:  The pres-
ence of the syndrome was associated with an in-
creased risk of CHD, MI and stroke in all sub-
jects, i.e. RR 2.96, 2.63 and 2.27 respectively
(all p<0.001) and this risk was greater than the
risk associated with any of the individual com-
ponents.  Dyslipidaemia was associated with an
increased risk for CHD (p<0.001) particularly
among patients with type 2 diabetes (RR 1.84;
p=0.001). Hypertension was associated with in-
creased risk for CHD, particularly in subjects with
NGT (RR 2.33; p<0.001).
Cardiovascular mortality in relation to the
metabolic syndrome: During the median follow-
up of 6.9 years 360 (10.0%) of the 3606 patients
had died, of them 209 (5.8%) died from CVD.
Total (18.0 vs 4.6%; p<0.001) and cardiovascu-
lar (12.0 vs 2.2%; p<0.001) mortality was in-
creased in subjects with compared to subjects
without the metabolic syndrome. In a multiple
regression analysis with cardiovascular mortal-
ity as the dependent variable and age, male sex,
LDL cholesterol, current smoking as independ-
ent variables, the relative risk of the metabolic
syndrome was 1.81 (p=0.002).  If the metabolic
syndrome was replaced by its components in the
analysis, microalbuminuria was the strongest risk
factor for cardiovascular death (RR 2.80,
p<0.001). The survival curves for all patients and
IFG/IGT patients are shown in Figure 10 (Cox
regression with adjustment for age and sex).
Figure 7. Prevalence (%) of the metabolic syndrome in 35-70 
year old male and female subjects with normal (NGT), 
impaired (IFG/IGT) and diabetic glucose tolerance .
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Table 13: Prevalence (%) of the components of the metabolic syndrome in males and 
females, aged 35-70 years, with NGT, IFG/IGT and type 2 diabetes.
 
         NGT      IFG/IGT   Type 2 DM 
 M F M F M F 
Obesity  76 36 86 51 92 78 
Dyslipidaemia 29 16 45 31 54 56 
Hypertension 23 24 31 35 55 59 
Microalbuminuria 4 3 7 6 22 12 
Insulin resistance* 25 25 58 59 87 89 
* as the highest quartile of HOMA-IR 
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4. Complications in patients
with the metabolic syndrome
(IV)
The patients with and without the metabolic
syndrome were matched for age, sex, duration of
diabetes and glycaemic control. Neither was there
any difference in total cholesterol, LDL choles-
terol concentrations nor in current smoking be-
tween the groups. The patients with the meta-
bolic syndrome had, as expected, higher BMI,
WHR, fasting C-peptide, triglyceride  (all p-val-
ues <0.001) and apoB concentrations (p=0.009)
as well as lower total HDL cholesterol (p<0.001),
HDL2 (p=0.008) and HDL3 cholesterol (p<0.001)
concentrations. The prevalence of hypertension
was also higher in the patients with than with-
out the metabolic syndrome (81 % vs 27 %,
p=0.001). The LDL particle size was smaller in
the patients with than without the metabolic syn-
drome (25.4±1.4 vs 26.4±1.1 nm, p<0.001).
The prevalence of diabetic complications is
seen in Table 14. To be able to study the role of
the metabolic syndrome in the prediction of mi-
cro- or macroalbuminuria, we excluded
microalbuminuria from the definition of the
metabolic syndrome for this analysis. The pa-
tients with the metabolic syndrome had a higher
Figure 9. Prevalence (%) of cardiovascular disease in relation 
to the metabolic syndrome in all subjects.
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Figure 8. Prevalence (%) of coronary heart disease in relation 
to the metabolic syndrome.
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prevalence of CVD (52 vs 21 %, p<0.001), mi-
cro- or macroalbuminuria (23 vs 7%, p=0.003)
and distal neuropathy (16 vs 6 %, p=0.048). In-
terestingly, severe retinopathy was only seen in
patients with the metabolic syndrome.
Risk factors for complications: In a multi-
ple logistic regression analysis (Table 15) with
the different complications as the dependent vari-
able the metabolic syndrome was associated with
CHD (RR 3.84, p<0.001) and microalbuminuria
(RR 3.99, p=0.01), whereas glycaemic control
(mean of HbA1c during the last 5 years) was re-
lated to neuropathy (RR 1.69, p=0.04), retinopa-
thy (RR 1.53, p=0.002) and microalbuminuria
(RR 1.54, p=0.01). LDL particle size was inde-
pendently of peripheral vascular disease associ-
ated with neuropathy (RR 0.58, p=0.04). When
the metabolic syndrome was replaced with its
components in the regression analysis hyperten-
sion was related to retinopathy (RR 2.24, p=0.04)
and microalbuminuria (RR 5.39, p=0.005),
whereas dyslipidaemia was associated with CHD
(RR 2.81, p<0.001).
Table 15: Risk factors for diabetic complications in 170 type 2 diabetic patients ( Study IV) 
Risk factor Coronary 
heart 
disease 
Neuropathy Retinopathy Micro-
albuminuria 
HbA1c  0 + ++ + 
Duration 0 0 + 0 
Metabolic 
syndrome 
++ 0 0 + 
Male sex 0 0 0 + 
Small LDL 0 + 0 0 
0 = not significant, + = p<0.05, ++ = p<0.01 
Results
Table 14: Chronic complications in diabetic patients with and without the metabolic 
syndrome. 
 MSDR+ MSDR- P-value 
Number (M/F) 85 (53/32) 85 (53/32)  
Retinopathy (%) 
    - none 
    - mild 
    - moderate 
    - severe 
 
52 
36 
4 
8 
 
59 
38 
4 
0 
 
0.44 
 
 
0.01 
Macular edema (%) 6 8 0.77 
AER >20µg/min (%)* 23 7 0.003 
Distal neuropathy (%) 
Elevated vibration threshold (%) 
16 
45 
6 
38 
0.048 
0.49 
Cardiovascular disease (%) 52 21 <0.001 
Coronary heart d isease (%) 
    - myocardial infarction (%) 
46 
12 
18 
2 
<0.001 
0.03 
Cerebrovascular disease (%) 6 1 0.21 
Peripheral vascular disease (%) 12 5 0.16 
* AER excluded from the definition of the metabolic syndrome.
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Discussion
1. Subjects and methods
1.1. Subjects
In Study I and II all available known MODY3
and GADA-positive diabetic subjects from the
Botnia Study in western Finland were included.
The type 1 diabetic control subjects (Study I-II)
were consecutive patients, representing more
than 90 % of the type 1 diabetic patients from
the outpatient clinic at Jakobstad Hospital, where
the majority of type 1 diabetic patients from that
region are followed.  The type 2 diabetic sub-
jects in Study IV represented a random sample
(aged 35-70 years) of type 2 diabetic patients from
the Botnia Study. Thus, all patients (excluding
those used for ophthalmological comparisons)
were from the same geographic region in west-
ern Finland. The subjects in study III, including
all 35-70 year-old subjects from the Botnia Study
in Finland and Sweden, should be representa-
tive for a Scandinavian population. According
to the results from the Botnia study the hetero-
geneity of diabetes can be depicted as in Figure
11.  In addition to the subgroups described in the
current study there seems to be interaction be-
tween type 1 and type 2 diabetes with possible
impact on the phenotype of diabetes (Li et al.
2000).
It is not always possible to exclude a selec-
tion bias in cross-sectional studies (Study I, II
and IV). This could result in selection of surviv-
ing patients if patients with complications die
prematurely. This is a particular problem in pa-
tients with high age (Study II). Some additional
available information was used to address this
issue. First, the prevalence of CHD was similar
in LADA and type 2 diabetic patients below 60
years of age (36% vs. 36%). Second, total mor-
tality during a median follow-up of 5.7 years was
similar in patients with LADA and type 2 diabe-
tes (17% and 20%). Third, a subgroup of LADA
and type 2 diabetic patients with short duration
and lower age did not show any differences in
prevalence of CHD. There was, however, a ten-
dency for lower cardiovascular mortality in the
LADA than in the type 2 diabetic patients (7.4%
vs. 12.4%), that could imply that LADA patients
have a higher mortality from other diabetic com-
plications. Obviously prospective studies are
needed to clarify this issue.
The limited number of patients in the study
groups is of course a problem when studying rare
diseases (Study I). However, the results of the
study are in line with other recently published
studies on complications in MODY3 (Velho et
al. 1996; Doria et al. 1999). A prospective fol-
low-up of MODY3 patients could further illus-
trate the natural course of this subgroup of dia-
betes.
1.2. Methods
Retinopathy: The diagnosis of DR was prin-
cipally based upon fundus photography and the
well validated alternative classification of the
Wisconsin Epidemiological Study of Diabetic
Retinopathy (Klein et al. 1986). In the type 1
diabetic patients the classification was based upon
(ophthalmologic) hospital records and photog-
raphy, which did not allow a precise classifica-
tion, and we chose to combine mild and moder-
ate retinopathy into one group in contrast to se-
vere retinopathy. Although the methods are not
completely compatible, the method used in the
type 1 diabetic patients should give a reliable
prevalence of any or severe retinopathy.
Microalbuminuria: In Study I, II and IV the
assessment of AER was based upon albumin ex-
cretion in overnight urine. If overnight urine was
not available (< 10 %), the ACR in morning urine
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was used. In Study III urine for the measurement
of AER was collected either during the OGTT
(n=1082) or overnight (n=1579). AER measured
overnight correlated with AER during the OGTT
(r=0.605, p<0.001, n=442). For the comparison
of the two methods subjects brought in overnight
urine on the morning of the OGTT. If we com-
pare the prevalence of microalbuminuria, meas-
ured overnight or during the OGTT, the preva-
lence in the different groups are virtually the
same. Only in diabetic patients was the preva-
lence of microalbuminuria lower using the AER
during the OGTT rather than overnight urine,
which most likely can be explained by the fact
that the OGTT was performed in diabetic pa-
tients only if their fasting blood glucose concen-
tration was < 10 mmol/l. When available (75%
of the diabetic patients) we used AER from over-
night urine.
Neuropathy: In all the subgroups studied the
diagnosis of distal neuropathy was based upon
the same clinical examination and a symptom
score (Young et al.1993), which makes compari-
son of the prevalence in different groups possi-
ble. The method represents a relatively simple
scoring technique for symptoms and signs which
is easy to apply in clinical practice.  A similar
method has proven to be useful in previous stud-
ies (Young et al. 1993; Franklin et al. 1990). The
measurement of vibration threshold was done by
two different devices: Biothesiometer (Biomedi-
cal Instruments, Ohio, USA) in Study I-II, and
Vibrameter (Somatomedic Productions,
Sollentuna, Sweden) in Study IV. The results
from two different control groups were used. The
control group for Biothesiometer represented all
ages while the control group for Vibrameter sub-
jects aged 35-70. The results were corrected for
age (Biothesiometer) and height (Vibrameter),
respectively.
Cardiovascular disease: In studies I, II and
IV ischaemic changes in resting ECG (Minne-
sota code) was used in addition to the medical
history. The prevalence of CHD is obviously un-
derestimated when using only questionnaires or
hospital records (Study III). Several studies have
shown a higher prevalence of abnormalities in
exercise ECG and heart perfusion in middle-aged
diabetic patients (Airaksinen 2001). This is
clearly a limitation of the methodology and we
cannot exclude that some of the patients without
coronary symptoms and with normal resting ECG
nevertheless had CHD. However, as the patients
had been treated in the local hospitals we also
had access to the hospital records. The diagnosis
of CHD in Study III was based upon a history of
typical chest pain or use of nitroglycerine or a
history of previous myocardial infarction. In a
subset of patients we also used ECG analysis in
addition to clinical data for the diagnosis of CHD.
As expected, the prevalence of CHD increased
in this subset, especially in subjects who fulfilled
the criteria for the metabolic syndrome (35 % vs
8 %), giving a RR of 3.97 (p<0.001, adjusted for
age and sex) for the metabolic syndrome.
Figure 11. The heterogeneity of diabetes.
type 1 DM
15 %
type 2 MSDR+
50 %
type 2 MSDR-
10 %
Mixed type 1 & 
2
10 %
MODY
5 %
LADA
10 %
Discussion
42
2. Complications in diabetic
subgroups
2.1. Retinopathy
In the patients with MODY3 diabetes (Study
I) the prevalence of mild retinopathy was 34%
and severe non-proliferative or proliferative retin-
opathy 13%, which was similar to the prevalence
seen in type 1 and type 2 diabetic patients
matched for duration of diabetes and HbA1c. The
current study is in agreement with results from
other studies in MODY3 patients and shows by
using qualified methods for assessing retinopa-
thy that MODY3 patients can develop severe
retinopathy (Velho et al. 1996; Iwasaki et al.
1998; Doria et al. 1999). The level of glycaemic
control was a strong determinant of retinopathy,
with an increase in the risk ratio by 3.1 for each
1 % increase in HbA1c. Although this figure is
higher than that observed in Swedish type 1 dia-
betic patients (1.37 with a 95% confidence in-
terval of 1.14 to 1.64) (Henricsson et al. 1996),
it should be kept in mind that the confidence in-
terval is wide (1.1 to 8.6) due to the small number
of subjects studied. In addition to hyperglycae-
mia, duration of diabetes was associated with
retinopathy. Based on results from screening in
MODY3 families, duration is obviously under-
estimated in many patients as the disease can be
undiagnosed for a long time, with possible in-
fluence on the development of complications.
We observed no differences in the prevalence
of retinopathy between LADA and matched type
2 diabetic patients (56 % vs 51 %). However, the
prevalence was clearly lower than in type 1 dia-
betic patients (76%) (Table 16). The prevalence
of retinopathy in both the type 1 and type 2 dia-
betic groups were in the reported range (Klein et
al. 1984a; Klein et al. 1984b; Henricsson et al.
1996). Both duration and glycaemic control were
related to retinopathy in the LADA patients, with
an increase in the risk ratio of 1.88 for each per-
cent increase in HbA1c.
There was no significant difference in the
prevalence of retinopathy between patients with
and without the metabolic syndrome (48 % vs.
41 %) (Study IV). Interestingly, severe retinopa-
thy was only seen in patients with the metabolic
syndrome. Despite this, the metabolic syndrome
did not predict overall retinopathy or moderate
or severe retinopathy in multiple logistic regres-
sion analyses. This can, of course, be due to the
relatively small number of patients with severe
retinopathy. When the metabolic syndrome was
replaced by its individual components, hyperten-
sion was an independent risk factor for retinopa-
thy (RR 2.24, p=0.04). In the UKPDS tight con-
trol of blood pressure decreased significantly the
progression rate of retinopathy (UKPDS 1998),
and the incidence of retinopathy was associated
with higher blood pressure  (Stratton et al. 2001).
2.2. Micro- and macroalbuminuria
In type 1 diabetic patients microalbuminuria
has been a strong predictor of subsequent devel-
opment of diabetic nephropathy (Mogensen et
al. 1984; Mathiesen et al. 1984). In patients with
type 2 diabetes elevated albumin excretion has
been regarded both as a marker of incipient ne-
phropathy and as a marker of vascular damage
and cardiovascular morbidity and mortality
(Mogensen et al. 1984; Dinneen et al.1997). In
accordance with some other studies both micro-
and macroalbuminuria was observed in the
MODY3 patients (Velho et al. 1996; Doria et al.
1999) (Study I). Four MODY3 patients had
macroalbuminuria, and one of them was being
treated for uraemia. In the MODY3 patients
HbA1c, but not the duration of the disease or hy-
pertension, was associated with
microalbuminuria. These data and the low preva-
lence of the features of the metabolic syndrome
strongly support the view that MODY3 patients
are susceptible to developing nephropathy as a
consequence of elevated blood glucose levels.
In the LADA patients (Study II) male sex but
not hypertension was associated with
microalbuminuria. This could either reflect the
lower prevalence of hypertension in the LADA
patients or suggest that in these patients,
Discussion
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microalbuminuria is not part of the metabolic
syndrome as suggested for type 2 diabetes (Groop
et al. 1993). Although we do not know whether
microalbuminuria in LADA patients reflects in-
cipient nephropathy or general vascular damage,
the lower prevalence of the features of the meta-
bolic syndrome in LADA patients supports the
former view. Also, in the LADA patients
microalbuminuria was associated with retinopa-
thy. This association is in keeping with findings
in type 1 diabetic patients, in whom retinopathy
is an almost obligate corollary of
microalbuminuria.
To study the role of the metabolic syndrome
in the prediction of micro-or macroalbuminuria,
we excluded microalbuminuria from the defini-
tion of the syndrome for this part of the study.
The patients with the metabolic syndrome had a
significantly higher prevalence of
microalbuminuria or macroalbuminuria (23 %
vs 7 %, p=0.003) than those without the syn-
drome. In the multiple regression analysis, the
metabolic syndrome (RR 3.99, p=0.01) was the
strongest predictor of albuminuria in addition to
male sex (RR 3.41, p=0.04) and the mean HbA1c
concentration (RR 1.54, p=0.01). Poor glycae-
mic control (Gall et al. 1997; Forsblom et al.
1998a) and male sex (Gall et al. 1997) have ear-
lier been reported as risk factors for
microalbuminuria. These results support the view
that microalbuminuria is associated with the
metabolic syndrome.
2.3. Neuropathy
In all the subgroups of diabetes the same
method was used to assess the prevalence of distal
neuropathy. In the MODY3 patients (Study I)
we found distal neuropathy in 24% of our
MODY3 patients compared to 13 % in the type
1 diabetic patients (p<0.001). In a French study
neuropathy was diagnosed only in 1 out of 27
MODY3 patients (Velho et al. 1996). However,
this study based diagnosis of neuropathy on pa-
tient records.  For comparison, in the UK Hospi-
tal Clinic Study (Young et al. 1993) almost simi-
lar diagnostic criteria as used in this study gave
a prevalence of 22.7% in type 1 diabetic (me-
dian age of 45 years and duration of 13 years)
Table 16: Prevalence (%) of chronic c omplications in diabetic subgroups. 
 MODY3 
 
n=57 
LADA 
 
n=59 
Type 1  
 
n=111 
Type 2   
MSDR+ 
n=85 
Type 2  
MSDR- 
n=85 
Age (years) 44±16 70±11 39±12 59±9 61±7 
Duration (years) 17±13 13±6 23±12 8±6 9±6 
HbA1c (%) 7.6±1.3  8.3±1.5 8.8±1.5 7.9±1.6 7.5±1.4 
Any retinopathy  
- severe 
47 
13 
51 
9 
76 
21 
48 
8 
41 
0 
Microalbuminuria 
- macroalbuminuria 
19  
8 
27  
4 
24  
 6 
23 
4 
7 
1 
Distal neuropathy  29 29 13 16 6 
CHD  16 56 4.5 46 18 
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and 32.1% in type 2 diabetic patients. If we used
the vibration threshold measured by the
Biothesiometer as the dependent variable and
duration of diabetes and HbA1c as independent
variables, only HbA1c predicted sensory neuropa-
thy.  If we used distal neuropathy as the depend-
ent variable, only duration of diabetes was weakly
associated with neuropathy. We think that the
most likely explanation for this discrepancy is
that vibration threshold represents a more stand-
ardised and sensitive indicator of distal sensory
neuropathy than the clinical score.
The prevalence of distal neuropathy was 29
% in the LADA and 27 % in the matched type 2
diabetic patients, which seem to be in the ex-
pected range (Young et al. 1993; Ziegler et al.
1993). The current study, with the LADA pa-
tients representing a group with lower C-pep-
tide concentrations, does not confirm the results
from a prospective Finnish study in which low
insulin values predicted peripheral neuropathy
(Partanen et al. 1995). Neither does it confirm
the theory that GADA could play a role in the
pathogenesis of diabetic nephropathy (Kaufman
et al. 1992; Hoeldtke et al. 2000). As glutamic
acid decarboxylase (GAD) is widely distributed
in the nervous system, it has been suggested that
circulating GADA could have an impact on the
function of GAD. Another explanation could be
that GADA reflects the presence of a systemic
inflammatory process with effects on both the β-
cell and peripheral nervous system (Hoeldtke et
al. 2000).
The prevalence of distal neuropathy was more
common in type 2 diabetic patients with the meta-
bolic syndrome than in those without (16% vs
6%; p=0.048), suggesting that the metabolic syn-
drome might modify the development of neuropa-
thy (Study IV). However, when duration of dia-
betes, mean HbA1c and the metabolic syndrome
were included in a multiple logistic regression
analysis, only mean HbA1c was an independent
risk factor. Of note, peripheral vascular disease
was also a strong independent predictor of neu-
ropathy (RR 10.1; p=0.004). It is, however, not
easy to distinguish between symptoms and signs
of peripheral vascular disease and neuropathy
clinically. A low ABI signifying peripheral vas-
cular disease has previously been reported to pre-
dict neuropathy (Adler et al. 1997). A novel find-
ing was that the LDL particle size (but not the
metabolic syndrome) was associated with neu-
ropathy and that this association was independ-
ent of the presence of peripheral vascular dis-
ease. How could the association between small
dense LDL particles and neuropathy be recon-
ciled? Oxidative stress and impaired n-6 essen-
tial fatty acid metabolism contribute to impaired
nerve conduction velocity in diabetic rats and can
be corrected by antioxidants like γ-linolenic acid
and α-lipoic acid (Van Dam et al. 1995; Cameron
et al. 1998). Small dense LDL particles are vul-
nerable to oxidation in the vessel wall (Steinberg
and Lewis 1997), but it is not known whether
the same is true in peripheral nerves. It is also
possible that small dense LDL particles could
contribute to impaired microcirculation of the
peripheral nerves and thereby cause impaired
nerve function.
2.4. Cardiovascular disease
Coronary heart disease was seen in 16% of
the MODY3 patients, which was higher than in
the type 1 (4.5%) but lower than in the type 2
diabetic patients (33%). This figure should also
be contrasted against a prevalence of 53 and 40
%, respectively, in newly diagnosed Finnish male
and female type 2 diabetic patients aged < 50
years (Uusitupa et al. 1985). One possible expla-
nation for the lower frequency of hypertension
and CHD in MODY3 than in type 2 diabetic pa-
tients, could be that MODY3 patients show nor-
mal or even increased insulin sensitivity and few
features of the metabolic syndrome (Lehto M et
al. 1997; Pearson et al. 2001; Tripathy et al.
2001).
The patients with the metabolic syndrome
(Study IV) reported a significantly higher preva-
lence of CHD and previous myocardial infarc-
tion compared to the patients without the meta-
bolic syndrome (Table 14).  There were no dif-
ferences between the patients with and without
the metabolic syndrome with respect to glycae-
mic control, current smoking or LDL cholesterol
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concentration. In addition to high triglyceride and
low HDL cholesterol concentrations, the patients
with the metabolic syndrome also had smaller
LDL particles compared to the patients without
the syndrome.  Small dense LDL particles are
highly atherogenic and may explain part of the
increased cardiovascular risk associated with
high triglycerides and low HDL cholesterol con-
centrations (Gray et al. 1997; Lamarche et al.
1997). A newly published study demonstrated a
relationship between the metabolic syndrome (de-
fined according to the WHO proposal), small
LDL particle size pattern and the occurrence of
preclinical atherosclerosis (intima-media thick-
ness) in healthy 58-year-old men (Hulthe et al.
2001). The definition of dyslipidaemia
(triglycerides >1.7 mmol/l or HDL cholesterol
<0.9 in males or <1.0 in females) had a sensitiv-
ity of 73 % and a specificity of 80 % to predict
small dense LDL particles, defined as a particle
size smaller than 25.5 nm (Austin et al. 1988).
The only risk factor for CHD identified in the
multiple regression analysis was the metabolic
syndrome with a risk rate of 3.84 (p<0.001). This
increased risk was mainly explained by the pres-
ence of dyslipidaemia (RR 2.8, p=0.007). In the
regression analysis, the mean HbA1c did not come
out as a significant risk factor for CHD. Although
there are prospective studies (Turner et al. 1998;
Lehto S 1997; Haffner 1999) suggesting an as-
sociation between hyperglycaemia and CVD, this
relationship is relatively weak and may be over-
shadowed by other risk factors like the other com-
ponents of the metabolic syndrome (Laakso
1999). In fact, we only saw an association be-
tween hyperglycaemia and CVD in the LADA
patients, a subgroup with few features of the
metabolic syndrome (Study II).
3. Cardiovascular risk and the
metabolic syndrome
Prevalence of the metabolic syndrome: In
previous studies the prevalence of the metabolic
syndrome has varied widely mainly due to dif-
ferent definitions of the syndrome or selection of
different subgroups (Rantala et al. 1999). In the
current study (Study III) the metabolic syndrome
was present in about 10% of subjects with NGT,
50% of subjects with IFG/IGT and 80% of sub-
jects with type 2 diabetes. In a Finnish popula-
tion-based study, a metabolic syndrome defined
as clustering of dyslipidaemia and insulin resist-
ance (defined as abnormal glucose tolerance or
fasting plasma insulin ≥13 mU/l) was present in
17% of non-diabetic men and 8 % of women
(Vanhala et al. 1997). In the ARIC study popu-
lation a combination of hypertension (blood pres-
sure >140/90mmHg or use of antihypertensive
treatment) and dyslipidaemia (triglycerides >2.26
mmol/l or HDL <0.9 mmol/l in men or <1.2 in
women) was observed in 10 % of the subjects
(Liese et al. 1997). In a newly published study of
391 healthy 58-year old Swedish men the preva-
lence of the metabolic syndrome (according to
the WHO proposal) was 16 % (Hulthe et al.
2000). This is very similar to the figure of 15 %
in our NGT male subjects.
The definition of the metabolic syndrome:
The prevalence of the metabolic syndrome and
its components is strongly dependent upon the
definition of the different components of the syn-
drome. Obesity defined by a high WHR was
clearly more common than obesity defined as
BMI >30 kg/m2. Using the proposed limits for
WHR of 0.9 for men and 0.85 for women 76 %
of men and 36% of women with NGT would be
considered abdominally obese whereas the cor-
responding figure using only BMI >30 kg/m2
would be 10% and 14%, respectively. A higher
cutoff level for WHR (1.0 in male and 0.9 in fe-
male subjects) increased the relative risk of CHD
associated with the syndrome in NGT subjects
from 1.73 (p=0.04) to 2.36 (p=0.002) but had
little influence on the risk in subjects with IFG/
IGT and type 2 diabetes.
The criteria for dyslipidaemia were more de-
pendent upon the presence of
hypertriglyceridemia than of low HDL-choles-
terol, which could present a problem in patients
with type 2 diabetes, in whom elevated triglyc-
eride levels may be secondary to hyperglycae-
mia (Taskinen et al. 1996).
The inclusion of microalbuminuria as part of
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the metabolic syndrome has been questioned
(Balkau et al. 1999) due to its rarity and lack of
association with insulin resistance in some stud-
ies (Hodge et al. 1996; Zavaroni et al. 1996). In
the current study a multiple logistic regression
analysis with microalbuminuria as dependent
factor clearly showed that all other components
of the syndrome, except for obesity, but includ-
ing insulin resistance were associated with
microalbuminuria (Table17). Whether insulin
resistance is involved in the pathogenesis of
microalbuminuria may be less important than the
fact that microalbuminuria indicates an advanced
stage of CVD thereby is associated with a high
cardiovascular mortality (Dinneen et al. 1997).
Insulin resistance and the metabolic syn-
drome: As many of the components of the meta-
bolic syndrome are associated with insulin re-
sistance, it has been suggested that the syndrome
should be called the insulin resistance syndrome
(Balkau et al. 1999). In the Bruneck Study the
prevalence of insulin resistance (defined as top
quintile of HOMA-IR) was 66 % in subjects with
IGT and 84 % in subjects with type 2 diabetes
(Bonora et al. 1998). The corresponding figure
in the current study using the top quartile of
HOMA-IR were very similar, 59 % in IFG/IGT
and 88 % in type 2 diabetic patients. Why is in-
sulin resistance then not included as a compo-
nent of the syndrome also in subjects with diabe-
tes in the WHO proposal? There are several ex-
planations for this. As insulin resistance defined
as top quartile of HOMA is seen in about 90% of
patients with type 2 diabetes, the prevalence of
the metabolic syndrome would not change much
if insulin resistance was included as a compo-
nent in this group (males: from 84% to73%; fe-
males: 78 to 71%). Secondly, much of the insu-
lin resistance in type 2 diabetes may be second-
ary to elevated glucose (Yki-Järvinen 1992) and
free fatty acid  (FFA) levels (Randle et al. 1963;
Boden 1997). It is not known whether the car-
diovascular risk associated with secondary insu-
lin resistance is the same as that associated with
insulin resistance in the prediabetic state. Finally,
and probably the most important argument
against including insulin resistance as a compo-
nent of the syndrome in patients with type 2 dia-
betes is that it is very difficult to quantitate insu-
lin resistance in a hyperglycaemic subject.
On the other hand, the finding that insulin
resistance predicted CVD in  subjects with IFG/
IGT suggests that it may be worthwhile to con-
sider it for the diagnosis of the metabolic syn-
drome in this subgroup. If we included insulin
resistance in the definition of the metabolic syn-
drome also in the IFG/IGT group, the prevalence
of the syndrome would be 33 % in females and
45 % in males compared with 42 % and 64 %
without it.
The metabolic syndrome and cardiovascu-
lar risk: The clinical importance of the meta-
bolic syndrome is related to its putative impact
on cardiovascular morbidity and mortality; in the
present study (Study III) the prevalence of CHD,
myocardial infarction and stroke were about 3-
fold higher in subjects with than without the
metabolic syndrome. Importantly, the presence
Table 17: Multiple logistic regression analysis with microalbuminuria as dependent variable 
and the components of the metabolic syndrome in 2414 subjects aged 35 – 70 years. 
Components RR (95 % CI) p-value 
Obesity 1.23 (0.78 – 1.92) 0.4 
Dyslipidemia 1.54 (1.12 – 2.11) 0.007 
Hypertension 2.77 (1.99 – 3.87) <0.001 
Insulin resistance 2.56 (1.73 – 3.81) <0.001 
                 Adjusted for age and sex 
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of the metabolic syndrome was associated with
an odds ratio for cardiovascular mortality of 1.8.
However, the number of deaths was relatively
small, without enough power to clearly define
risk of total and cardiovascular death in sub-
groups (Figure 10). Therefore the data regard-
ing mortality should only be considered sugges-
tive.
Which of the components or combinations
of components are associated with the increased
cardiovascular risk? The combination of obesity
and hypertension or dyslipidaemia was the most
common risk factor combination in subjects with
IFG/IGT and diabetes. However, given the high
frequency of obesity in this population it had lit-
tle influence on the relative risk of CHD in sub-
jects with NGT, IFG/IGT and diabetes (1.15, 1.79
and 1.48). The combination of hypertension and
dyslipidaemia was the second most common risk
factor combination in subjects with NGT (8 and
5% in men and women), IFG/IGT (16 and 14%)
and diabetes (31 and 36%), and thereby had the
greatest influence on the CHD risk associated
with the syndrome. While hypertension was
strongly associated with CHD in the NGT group
(RR 2.33;p<0.001) dyslipidaemia was related to
CHD in the patients with type 2 diabetes (RR1.84;
p=0.001). It is also possible that treatment of
hypertension and dyslipidaemia could influence
the results. The latter is unlikely because only
about 1% of the patients received lipid-lowering
treatment. Antihypertensive therapy varied from
15.5% in the NGT to 21.9% in the IFG/IGT
group and 46.3% in the type 2 diabetic patients,
with even distribution of different treatment
modalities (diuretics 28%, betablockers 42%,
calcium antagonists 21%, ACE inhibitors 29%).
 In the current study microalbuminuria was
associated with a markedly increased risk of car-
diovascular death  (RR 2.80; p < 0.001). This is
in congruence with several other studies in which
microalbuminuria has been a strong predictor of
cardiovascular morbidity and mortality (Kuusisto
et al. 1995; Jensen et al. 1997; Dinneen et al.
1997; Borch-Johnsen et al. 1999).
Microalbuminuria has also been related to an
increased transcapillary albumin leakage (Jensen
et al. 1995), suggesting that microalbuminuria
represents a surrogate measure of endothelial dys-
function.
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Summary and conclusions
1. MODY3 (Study I): Diabetic retinopathy,
nephropathy and neuropathy were as common
in MODY3 patients as in type 1 and type 2 dia-
betic patients matched for duration and glycae-
mic control and these complications were clearly
determined by the degree of glycaemic control.
As subjects with MODY3 diabetes seem to be
sensitive to elevated glucose levels and the dis-
ease can be undiagnosed for years, screening for
diabetes in families with MODY3 diabetes should
be recommended to initiate early treatment and
thereby prevent the development of
microangiopathic complications.
2. LADA (Study II): LADA patients have
fewer features of the metabolic syndrome than
type 2 diabetic patients, and glycaemic control
seems to be a more important risk factor for retin-
opathy and CHD in LADA than in type 2 dia-
betic patients. The latter finding could be due to
the fact that fewer risk factors are operative in
patients with LADA. The tendency for lower car-
diovascular mortality in the LADA compared
with the type 2 diabetic patients has to be con-
firmed in a larger prospective study.
3. The metabolic syndrome (Study III): The
clustering of cardiovascular risk factors called
the metabolic syndrome was seen in about 10%
of subjects with NGT, 50% of subjects with IFG/
IGT and 80% of subjects with type 2 diabetes
when using a definition based on that proposed
by the WHO. It confers an increased risk of car-
diovascular morbidity and mortality. The identi-
fication of the metabolic syndrome may there-
fore be important in the risk assessment and treat-
ment of patients not only with diabetes, but also
with hypertension or obesity. The WHO proposal
may provide a useful tool for the comparison of
data among studies.
4. Influence of the metabolic syndrome on
chronic diabetic complications  (Study IV): In
addition to hyperglycaemia the risk of chronic
diabetic complications is modified by the pres-
ence of some of the components of the metabolic
syndrome, i.e. hypertension increases the risk for
retinopathy and albuminuria, whereas the pres-
ence of small dense LDL particles seems to in-
crease the risk for neuropathy.  These data not
only re-emphasise the need for multifactorial in-
tervention in patients with type 2 diabetes, but
also provide a putative novel target for treatment
influencing LDL particle size.
Taken together, the genetic, immunological
and metabolic heterogeneity of diabetes is an im-
portant determinant of the outcome of the dis-
ease.
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